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Abstract
Diabetes is a risk factor for stroke and vascular dementia. Clinical studies using
gadolinium-magnetic resonance imaging techniques have shown diabetic patients exhibit a
permeability increase at the blood-brain barrier (BBB) (Starr et al, 2003). The BBB, a
vascular interface at the level of brain microvascular vessels, functions to provide nutrients
and oxygen from the peripheral circulation, mediates waste efflux from the brain, and
protects the brain from toxins. These functions are due to the presence of tight junction
proteins. Animal studies have shown increased BBB permeability is due to a decrease in
these proteins (Hawkins et al, 2007). Based on these studies and using the streptozotocin
(STZ) model of diabetes, I hypothesized that the permeability and molecular changes can
be attenuated by minocycline, a tetracycline known to cross the BBB. STZ animals treated
with minocycline exhibited a decrease in permeability and an increase in the tight junction
protein, claudin-5. Previous studies have shown that the pro-angiogenic and permeability
cytokine, vascular endothelial growth factor (VEGF), is able to influence claudin-5
expression (Argaw et al, 2009). Therefore, VEGF may be involved in a minocyclineinduced increase in claudin-5 expression. VEGF significantly increased in STZ animals with
minocycline treatment. Additionally, there was a significant increase in expression of the
VEGF receptor, Flt-1, of control animals treated with minocycline, and a similar trend in
minocycline-treated STZ animals. However, there were no changes in the other VEGF
receptors. Based on these results, I hypothesized that VEGF might exert its effects on the
BBB in diabetes. Although there were no changes in VEGF, there was a glucosedependent change in PLCγ, a downstream signaling molecule involved in proliferation,
which might help explain the permeability change observed in diabetes.
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Chapter 1: Introduction
Diabetes
Diabetes mellitus is a metabolic disorder that is characterized by hyperglycemia.
It is generally classified into two types: Type I (T1D) and Type II (T2D). T1D is typically
diagnosed in children and young adults and is due to auto-immune destruction of the
beta cells of the pancreas. Thus, no insulin is produced, and patients with this disease
are insulin-dependent via injections or a pump. The other pancreatic islets that secrete
glucagon, somatostatin, and pancreatic polypeptide remain intact. The symptoms of
T1D are increased thirst, urination, hunger and weight loss. Additionally, ketoacidosis
and dyslipidemia may be present. Ketoacidosis is due to reduced insulin levels,
decreased glucose use, and an increase in gluconeogenesis (Trachtenbarg, 2005).
Insulin deficiency leads to uncontrolled beta-oxidation of free fatty acids, which are
converted to ketone bodies by the liver. Poorly controlled T1D can lead to
hypertriglyceridemia and reduced HDL, but insulin therapy can alleviate these
abnormalities (Goldberg, 2001). T1D has a genetic component; however,
environmental factors could be involved in the pathogenesis of the disease. Others
have proposed that T1D is triggered by a virus, perhaps Coxsackie or rubella viruses
(Alba et al., 2005).
T2D is characterized by insulin resistance and over time an insufficient
production of insulin. Patients with T2D exhibit similar symptoms to those with type I
diabetes. The development of T2D is likely a combination of genetic factors and
lifestyle habits. T2D is associated with poor lifestyle habits such as lack of exercise and
poor diet. Patients develop insulin resistance, which is the inability to utilize insulin at
normal levels. Additionally, the liver, which normally stores glucose as glycogen, will
1

release abnormal amounts of glucose into the blood. Elevated triglycerides, low HDL-C,
and LDL-C are evident in T2D (Kumar and Singh, 2010). Skeletal muscle, a target
tissue for glucose uptake, becomes insulin resistant (Olefsky and Nolan, 1995).
Management of T2D has been focused on lifestyle changes such as incorporating diet
and exercise into routine, lowering cardiovascular risks, and managing glucose levels
within normal range. Treatment for T2D typically involves anti-diabetic medications
such as metformin, sulfonylureas, and thiazolidinediones. The glucose-lowering effect of
metformin is due to its ability to reduce hepatic glucose production and increase
peripheral glucose uptake (Bailey et al., 1996). Sulfonylureas bind to a receptor that is
a component of the ATP-sensitive K+ channel in the beta cell. Upon binding, the ATPsensitive K+ channels close, which will lead to increased insulin secretion.
Thiazolidinediones are ligands for peroxisome-proliferator-activated receptor γ (PPARγ),
a nuclear transcription factor found in adipose tissue. PPARγ is important for adipocyte
differentiation, proliferation, fatty acid uptake, and storage. Thiazolidinediones act by
promoting the fatty acid uptake and storage (Yki-Järvinen, 2004). Insulin treatment may
be required as well.
Worldwide, diabetes affects approximately 171 million people, and this number is
likely to increase to about 336 million by 2030 (Wild et al., 2004). According to the
National Diabetes Data Sheet compiled by the Centers of Disease Control and
Prevention (2011), 25.8 million people, or 8.3% of the population in the United States, is
affected by diabetes. The American Diabetes Association reports that diabetes is the
seventh leading cause of death but is likely to be underreported as a cause of death.
The cost of diabetes is staggering with a total of $174 billion, of which $116 billion is due
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to direct costs and $58 billion due to indirect costs such as disability, work loss, and
premature mortality (Centers of Disease Control and Prevention, 2011). Moreover, the
American Diabetes Association estimates that the total cost increases to $218 billion
when factoring undiagnosed diabetes, prediabetes, and gestational diabetes.
Diabetic complications are characterized by changes in the macro- and
microvasculature. Macrovascular changes in diabetes result in cardiovascular disease.
An estimated 80% of diabetic patients die from cardiovascular disease. Of those deaths
about 75% result from coronary artery disease (CAD) with the remaining being due to
cerebrovascular disease, peripheral or other macrovascular disease (Cocherri, 2007).
Separately, CAD and diabetes are associated with endothelial dysfunction; however,
diabetes leads to further endothelial dysfunction in patients with CAD (Keymel et al
2011). Diabetic patients have a greater number of coronary arteries with diffuse
distribution of atherosclerotic lesions compared to non-diabetics, and similar
characteristics are seen in the peripheral vasculature (Milicevic et al., 2008). There is a
one-to-four fold increase in stroke and stroke-related events due to diabetes (Cocherri,
2007).
Microvascular changes in diabetes can lead to poor wound healing, nephropathy,
retinopathy, and neuropathy. Hyperglycemia leads to endothelial dysfunction by
altering endothelial production of vasoconstrictor prostaglandins and affects endothelial
cell matrix production leading to the thickening of the basement membrane (Hsueh and
Anderson, 1992). Poor wound healing in diabetes is due to a host of factors, including
impaired or decreased growth factor production and angiogenic response (Brem and
Tomic-Canic, 2007). The angiogenic response is decreased because of reduced
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vascular endothelial growth factor (VEGF) and stromal-derived growth factor-1α (SDF1α). VEGF induces activation of endothelial nitric oxide synthase (eNOS), resulting in
increased NO levels. NO triggers the mobilization of bone marrow endothelial
progenitor cells into circulation. SDF-1α causes these cells to move to the site of injury
(Brem and Tomic-Canic, 2007). Changes in the renal vasculature occur in diabetes
with increased glomerular capillary growth in the early stages of the disease.
Hyperglycermia is believed to induce protein kinase C and increase advanced glycation
end-products that can lead to microvascular changes (Guo et al., 2005). Diabetic
retinopathy constitutes a host of symptoms, including microaneurysms that will
eventually lead to macular edema, ischemic changes, microvascular abnormalities, and
proliferative changes (Antonetti et al., 2012). Diabetes can contribute to various
neuropathies, such as abnormal sensation and pain (Obrosova, 2009).

Cognitive

impairment occurs because of inflammation in the brain, affecting the blood vessels and
causing atrophy of brain tissue (Novak et al., 2011). Additionally, diabetes has also
been linked to the development of Alzheimer’s disease with both diseases having
overlapping features such as poor glycemic control and impaired insulin function
(Moreira et al., 2007). Insulin signaling is believed to be involved in generation of Aβ
peptides as well as limiting its degradation. Furthermore, decreased glucose
metabolism has been observed, which includes decreased enzyme activity (Moreira et
al., 2007). Diabetes is also an independent risk factor for stroke and vascular
dementias (Abbott et al., 1987), and changes in the blood-brain barrier may play a part
in these disease processes.

4

Blood-brain barrier (BBB)
The brain is at the center of the central nervous system. It coordinates and
integrates all the signals for the body to function properly. Therefore, the brain requires
protection from the rest of the body without compromising its requirement for nutrients,
such as oxygen and glucose. The BBB functions to protect the brain by inhibiting toxins
in the peripheral circulation from entering the brain, while allowing for nutrients to enter
through the barrier. Furthermore, it mediates waste efflux from brain to blood and
maintains a constant environment in the brain.
The concept of the BBB originated with the studies of Paul Ehrlich in 1885 who
observed that water-soluble dyes injected into the circulatory system stained all organs
except for the brain and spinal cord (Hawkins and Davis, 2005). His student, Edwin
Goldmann, injected dyes into the cerebral spinal fluid, which stained the brain but not
the rest of the body (Hawkins and Davis, 2005). These observations suggested that a
barrier must exist separating the brain and central nervous system from the peripheral
circulation. Studies with silver nitrate demonstrated differences in the nervous system
compared to the periphery (Dempsey and Wislocki, 1954). However, it was not until the
1960s when scientists were able to confirm the existence of a barrier at the structural
level. Electron microscopy showed that high doses of exogenous peroxidase failed to
penetrate the brain vascular endothelium and remained in the lumina of blood vessels
and in a few micropinocytotic vesicles within the endothelium. This finding led to the
conclusion that tight junctions probably were responsible for preventing intercellular
passage of peroxidase (Reese and Karnovsky, 1967). Brightman and Reese (1969)
demonstrated in separate experiments using intravascular injections of peroxidase and
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lanthanum hydroxide that tight junctions were present, separating the vascular lumina
from the underlying spaces. Furthermore, they confirmed that the tight junctions (as
described below) in the vascular endothelium have a pentalaminar configuration, which
is distinct from gap junctions that have a seven-layer configuration (Brightman and
Reese, 1969).
The BBB is comprised of endothelial cells that line cerebral microvessels. These
endothelial cells are characterized by few pinocytic vesicles, the absence of
fenestrations, and a high number of mitochondria (Bernacki et al., 2008). They originate
from permeable capillaries of the perineural vascular plexus and invade the embryonic
neuroectoderm to form intraneural capillaries (Wolburg et al., 1994). The ability of the
BBB to perform its functions is due to the presence of tight junctions, which hold the
endothelial cells close together. The tight junction complex is composed of tight
junction and adherens junction proteins (Figure 1). Tight junction proteins include
junctional adhesion molecules (JAMs), occludin, claudins, and membrane associated
guanylate kinase-like proteins. JAMs are single membrane-spanning proteins are
involved in the maintenance and formation of the barrier (Abbott et al., 2006). Occludin
is a transmembrane protein that functions to increase electrical resistance, and can
interact with zona occludens protein 1 (ZO-1) in the cytoplasmic side (Hawkins and
Davis, 2005; Abbott et al., 2006). The claudin family consists of four transmembrane
domains, and claudin-3 and -5 are expressed in endothelial cells of the BBB. They
seem to be the primary building protein of the tight junctions (Bernacki et al., 2008).
The membrane associated guanylate kinase-like proteins are accessory proteins found
in the cytoplasm that enable protein-protein interactions. Two of these proteins have
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been identified at the tight junction: zona occludens-1 (ZO-1) and zona occludens-2
(ZO-2). ZO-1 links occludin to the actin cytoskeleton, and ZO-2 binds to structural
constituents of the tight junction (Hawkins and Davis, 2005). Adherens junctions are
also “tightening” structures between endothelial cells and are composed of cadherins.
These cadherins bind to the cytoskeleton via α-, β-, and γ-catenins. It is thought that
ZO-1 and catenins interact with each other, suggesting that tight and adherens junctions
cooperate in maintaining the BBB (Bernacki et al., 2008).
The tight junction complex does not allow for paracellular transport of watersoluble agents and polar drugs. However, the endothelial cells have various transport
systems to allow for nutrients from the peripheral circulation to enter the brain and for
waste to efflux from brain to blood. Gases and lipophilic molecules are capable of
transcellular movement. Glucose and amino acids have the transport carriers, GLUT-1
and LAT1 and others, respectively, to cross the BBB (Abbott et al., 2006). Some
transport systems are energy-dependent, such as P-glycoprotein (Pgp), multidrug
resistant protein (MRP), breast cancer resistance protein (BCRP), organic anion
transporting polypeptides (OATP), and organic anion transporters (OAT), which efflux
molecules from the brain into the blood and have the potential to reduce the penetration
of drugs into the brain (Zlokovic, 2008). Pgp localizes on the luminal membrane of
endothelial cells. MRPs are also found in the luminal membrane, and are able to
transport organic anions and neutral organic drugs (Bernacki et al.,2008). OATPs are
expressed on both luminal and abluminal membranes of endothelial cells, and are
involved in the elimination of xenobiotics (Tamai et al., 2000), and amphipathic organic
solutes (Bernacki et al, 2008). OATs, particularly OAT3, are expressed in brain
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Figure 1.1. The organization of the tight junction. The tight junction is
comprised of occludin, claudin 3/5, and JAMs, which form a tight seal between
endothelial cells. The tight junction proteins also interact with the membrane
associated guanylate kinase-like proteins, such as ZO-1 and ZO-2, that are found
in the cytoplasm of the endothelial cells. ZO-1 and -2 link tight junction proteins to
the actin cytoskeleton and other accessory proteins in the cytoplasm.
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capillaries on the abluminal side, and its substrates include amphipathic organic anions,
hydrophilic organic anions, and organic cations (Ohtsuki, 2004). Insulin and transferrin
are taken up by receptor-mediated transcytosis while plasma proteins are transferred by
absorptive transcytosis if they undergo cationization (Abbott et al., 2006). Ion
transporters such as Na+/K+-ATPases, Na+-K+-2Cl- cotransporter, and the Na+/H+ and
Cl-/HCO3- exchangers are also present.
The endothelial cells that line the cerebrovasculature are supported and interact
with other structures to form the neurovascular unit (NVU). The NVU comprises
astrocytes, neurons, and pericytes interacting with the smooth muscle and endothelial
cells of the microvessel (Hawkins & Davis, 2005; Abbott et al., 2006). Anatomically,
astrocytes wrap around the microvessels with their endfeet making contact with the
vessel wall (Nedergaard et al., 2003). Furthermore, astrocytes secrete various growth
factors such vascular endothelial growth factor (VEGF) during retinal angiogenesis, and
continue to form and maintain the blood-retinal barrier (Uemura et al, 2008). Astrocytes
have a role in inducing BBB properties in vitro (Rubin et al., 1991). It has been reported
that with astrocyte loss there is tight junction disruption and loss of BBB integrity (Willis
et al., 2004). Neurons are highly metabolic, and therefore have a close relationship with
endothelial cells. With astrocytes as the intermediary, neurons and endothelial cells
have bi-directional communication.

The arrangement of neurons and microvessels

varies depending on location within the brain. In grey matter, microvessels grow in
hexagonal arrays whereas, in white matter, they are arranged in line with the axons (del
Zoppo, 2010). Neurons modulate BBB function, but it is not known if they are involved
in BBB development (Hawkins and Davis, 2005). Pericytes encircle the wall of the
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microvessel, and their processes can penetrate the basement membrane and make
contact with the endothelium (Hirschi and D’Amore, 1996). They regulate microvessel
diameter by constricting the vascular wall (Peppiatt et al., 2006; Bell et al., 2010). They
also regulate endothelial cell activity and mediate inflammation (Bernacki et al., 2008).
Alterations in the BBB have been implicated in aging and many diseases.
Research has focused on the role of BBB dysfunction in neurodegenerative diseases
such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic
lateral sclerosis (ALS). In Alzheimer’s disease, there is upregulation of GLUT1 and
increased glucose transport. Furthermore, there is also a decrease in Pgp, leading to
an increase in amyloid-β (Abbott et al., 2006). Low activity of Pgp has been observed in
Parkinson’s disease (Abbott et al., 2006; Zlokovic, 2008). Leukocyte extravasation
across the endothelium is believed to occur in multiple sclerosis, and BBB breakdown is
thought to lead to the pathogenesis of ALS (Zlokovic, 2008). BBB dysfunction has also
been implicated in inflammation, hypoxia/ischemia, pain, and human immunodeficiency
virus-1 (HIV-1) infection (Hawkins and Davis, 2005; Abbott et al., 2006; Zlokovic, 2008).

The BBB in Diabetes
BBB dysfunction has been well established in diabetes. Changes in glucose and
amino acid transport, structural and molecular alterations, and permeability have been
observed in diabetic animal models. Studies regarding glucose transport during
hyperglycemia have yielded mixed results. Gjedde et al. (1981) showed that glucose
transport decreased in diabetic rats despite the fact that cerebral blood flow did not
change in either the diabetic or control group. These results were supported by a study
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by McCall et al. (1982). However, Pelligrino et al. (1990) demonstrated that glucose
transport increased in chronically hyperglycemic diabetic rats compared to controls.
However, other studies have shown that hypoglycemia increases glucose transport
across the BBB (Simpson et al., 1999).
Transport of amino acids into the brain is important for its function. Many amino
acids, such as tryptophan and tyrosine, are precursors for neurotransmitters in the brain
and central nervous system. It has been shown that transport of the amino acids
tryptophan, tyrosine, and lysine does not change in diabetic rats versus control.
Ketone-body transport in the form of β-hydroxybutyrate is lower in diabetic animals and
is restored or increased upon insulin treatment (McCall et al., 1982). Furthermore,
glutamate transport at the BBB is not affected by diabetes in two rat models of diabetes
(Hawkins, 2009). Additionally, elevated plasma amino acids leads to a reduced flux of
large neutral amino acids across the luminal membrane of the BBB (Mann et al., 2003).
Structural and molecular changes of the BBB are evident in diabetes. Capillary
basement membrane thickening occurs, and the density of transcytotic vesicles
increases (Tolia et al., 2005). Additionally, there have been reports of changes in tight
junction protein expression. It has been reported that diabetic rats not treated with
insulin have a reduced occludin expression compared to insulin-treated or control rats
whereas ZO-1 remained unaltered (Chehade et al., 2002). Hawkins et al. (2007) saw a
similar decrease in occludin content, which together with an increase in MMP resulted in
a permeability increase. As diabetes progressed, there was further disruption in the
BBB and a region-specific permeability increase (Huber et al., 2006). Tight junction
protein expression and permeability changes can be prevented with the administration
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of seasmol, a natural antioxidant (VanGilder et al., 2009). Additionally, changes in the
transport systems at the BBB have been observed in diabetes. Hawkins et al. (2007)
have demonstrated decreased permeability to fluorescein, a marker for paracellular
permeability as well as a substrate for OAT3 and MRP2, in diabetic rats. In their study,
decreased permeability of fluorescein was in conjunction with an increase in MRP2
protein expression, but not OAT3 expression (Hawkins et al., 2007). Other transport
systems and receptors involved in brain efflux are also affected in diabetes. It has been
shown that low-density lipoprotein receptor related protein 1 (LRP1), a transporter at the
BBB responsible for amyloid-β peptide (Aβ) clearance, is down-regulated in an animal
model of diabetes, and clearance of Aβ is significantly decreased (Hong et al., 2009).
Additionally, it has been demonstrated that the receptor for advanced glycation end
products (RAGE) is up-regulated at the BBB leading to the deposition of Aβ in the brain
(Liu et al., 2009).
Changes in permeability to various substances can be dependent on the duration
of diabetes. Studies have demonstrated inconsistent results on albumin permeability.
In one study, albumin permeability increased (Bouchard et al., 2002); however, in
another study albumin permeability remained unaltered (Dai et al., 2002). Interestingly,
permeability of sucrose did not change in an experimental model of diabetes as the
disease progressed (Bradbury et al., 1991). Clinical studies using gadolinium-magnetic
resonance imaging techniques showed a BBB permeability increase in diabetic patients
compared to control patients (Starr et al., 2003). Lacunar infarcts, or small
microvascular strokes, are common in diabetes, and it has been suggested that BBB
failure, that is, leakage of the walls of small cerebral vessels, may be a mechanism

12

(Wardlaw et al., 2003). The mechanism of the observed permeability changes is not
known. Other studies at the blood-retinal barrier showed similar events, and implicated
vascular endothelial growth factor (VEGF) as likely candidate for the observed
permeability change (Antonetti et al., 1998).

Vascular Endothelial Growth Factor (VEGF)
The VEGF family
The VEGF family consists of several members, VEGF-A, -B, -C, -D, -E, -F and
placenta growth factor (PLGF), but the most studied is VEGF-A. They are dimeric
glycoproteins that act through three cell surface receptor tyrosine kinases, known as the
VEGF receptors (VEGFRs). VEGF-A, -B, and PLGF bind to VEGFR-1 (Flt-1); VEGF-A
and –E bind to VEGFR-2 (Flk-1); VEGF-C and –D bind to VEGFR-3; and VEGF-F binds
to both Flk-1 and Flt-1 (Olsson et al., 2006). Alternative splicing results in various forms
of VEGF-A: VEGF-A121, -A145, -A165, -A189, and –A206 (Olsson et al., 2006), with VEGFA165 being the most abundant human isoform (Wirostko et al., 2008) (Figure 1.2).
VEGF-A is important for vasculogenesis (blood vessel growth from endothelial
progenitor cells) and angiogenesis (blood vessel growth from pre-existing vessels). If
there is inactivation of a VEGF allele, embryonic lethality occurs at embryonic day 11-12
in mice and tetraploid embryos, resulting in vascular defects and cardiovascular
abnormalities (Carmeliet et al., 1996; Otrock et al., 2007; Lohela et al., 2009). VEGF
expression is down-regulated after embryogenesis (Breier et al., 1992), but is upregulated during physiological and pathological angiogenesis (Ferrera et al., 2003).
Additionally, VEGF is important for neurogenesis, and reduced levels of VEGF leads to
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Figure 1.2. The isoforms of VEGF. Alternative splicing of VEGF
yields various isoforms, with VEGF165 being the most studied isoform.

neurodegeneration by impairing the perfusion of neural tissue (Storkebaum and
Carmelier, 2004).
VEGF Receptors
The VEGF receptors are cell surface tyrosine kinase receptors. VEGFR-1,
henceforth called Flt-1, acts as a decoy receptor by sequestering VEGF and regulates
the interaction between VEGF and VEGFR-2 (Flk-1) by sequestering VEGF (Wirostko
et al., 2008). Flt-1 is important for blood vessel development during embryogenesis,
and plays an important role in pathological angiogenesis and wound healing by the
interaction with Flk-1 (Cebe-Suarez et al., 2006). Flt-1 has poor catalytic activity
compared to Flk-1 and the downstream signaling pathways upon its activation are not
well known. Flk-1 is involved in permeability, angiogenesis, vasculogenesis, and
proliferation (Holmes et al., 2007; Wirostko et al., 2008). VEGFR-3 is important for
wound healing, and sFlt-1 (soluble VEGFR-1) scavenges available VEGF (Wirostko et
al., 2008). Flk-1 and VEGFR-3 are also involved in lymphatic angiogenesis (Cebe14

Suarez et al., 2006). These receptors have an extracellular domain with
immunoglobulin-like folds, followed by a transmembrane region, a tyrosine-kinase
domain, and kinase insert, ending with a C-terminal tail (Wirostko et al., 2008). VEGF
exerts its effect by binding to Flt-1 and Flk-1 receptors as well as the neuropilin
receptors, NP-1 and NP-2. VEGF binding leads to dimerization and subsequent
autophosphorylation. This action can lead to either increased permeability or
angiogenesis (Figure 1.3).
Flk-1 activation can lead to proliferation, migration, survival, and permeability.
Proliferation is due to the phosphorylation of tyrosine 1175, leading to Erk
phosphorylation via PLCγ recruitment and a PKC-dependent pathway. Upon activation
at tyrosine 1175, PLCγ is phosphorylated and then hydrolyzes phosphatidylinositol
(4,5)-bisphosphate into diacyglycerol (DAG) and inositol (1,4,5)-triphosphate (IP3). IP3
increases intracellular calcium while DAG activates protein kinase C (PKC), which can
then activate the Erk signaling pathway.
Migration of endothelial cells can occur due to the phosphorylation of either
tyrosine 1214 or 951. Phosphorylation of tyrosine 1214 allows for the activation of the
p38 MAPK signaling pathway and recruitment of Hsp27 for actin remodeling. Tyrosine
951 activation leads to phosphorylation of Src and subsequent actin reorganization.
Migration can also occur with the phosphorylation of tyrosine 1175, with the subsequent
activation of PI3K and formation of PIP3. PIP3 leads to activation of Rho, which
ultimately leads to actin reorganization and migration. Phosphorylation of tyrosine 1175
can also lead to migration via the recruitment of FAK, followed by focal adhesion
turnover. Cell survival occurs with the phosphorylation of tyrosine 1175, leading to
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Figure 1.3. Schematic diagram of VEGF signaling. VEGF is able to
bind to two classes of receptors: VEGFRs and the neuropilins. The
VEGFRs are Flt-1 and Flk-1, a decoy receptor and the active receptor,
respectively. Neuropilins enhance VEGF/Flk-1 signaling and are
required for full activation of Flk-1. The binding of VEGF to the
receptors causes dimerization and autophosphorylation of specific
tyrosine residues on the Flk-1 receptor. Phosphorylation of these
tyrosine residues leads to signaling pathways involved in permeability,
migration, and proliferation. SEMA 3A is an antagonist of VEGF, and
exerts its effects by binding to the neuropilin receptors, thereby blocking
VEGF from binding to this class of receptors. SEMA 3A is also known
as a permeability factor as well, independent of VEGF-induced
permeability. (Figure courtesy of Dr. Richard Egleton)
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PIP3 formation via PI3K. PIP3 causes phosphorylation of Akt/PKB, which inhibits the
pro-apoptotic protein, Bad, and caspase-9 activation.
Permeability of the endothelium occurs via activation of tyrosine 951 or 1175.
Phosphorylation at tyrosine 951 leads to activation of Src and actin reorganization as
seen during migration. At tyrosine 1175, PI3K is activated, followed by PIP3 formation.
As with cell survival, PIP3 causes phosphorylation of Akt/PKB; however, Akt will lead to
the activation of endothelial nitric oxide synthase (eNOS). eNOS will lead to an
increase in nitric oxide (NO) production, which will facilitate a permeability increase in
endothelial cells.
Neuropilin Receptors
The neuropilin receptors are transmembrane glycoproteins important for axonal
guidance, angiogenesis, tumorigenesis, and are involved in the immunologic response
(Sulpice et al., 2008). The receptors denoted NP-1 and NP-2 act as co-receptors for
class III semaphorins (see next section) and members of the VEGF family. They have
large extracellular domains and a short cytoplasmic tail that lacks enzymatic activity
(Sulpice et al., 2008). However, the lack of enzymatic activity remains unclear as tumor
cells lack the Flk-1 receptor, but express neuropilin receptors (Geretti et al., 2008).
Their extracellular domains consist of (1) a signal sequence; (2) two complement
factors, a1 and a2; (3) two coagulation factors, b1 and b2; and a (4) c domain, which is
homologous to A5. The length of these domains is similar between the two receptors,
but they have varying degrees of conservation (Kolodkin et al., 1997). The binding site
for VEGF is located in the b1 and b2 domains whereas SEMA 3A requires both a and b
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domains (Geretti et al., 2008; Sulpice et al., 2008). Furthermore, NP-1 and NP-2 bind to
VEGF-A165 with different affinities
NP-1 was initially identified as an antigen to the antibody, A5, which was raised
against proteins in the optical tectum of Xenopus tadpoles (Geretti et al., 2008; PelletMany et al., 2008). NP-1 has a large extracellular domain followed by a short
transmembrane domain and an intracellular domain. It is expressed in neural tissues,
particularly during development of the central nervous system, but is also present in
non-neuronal tissues in adults particularly in the placenta, heart, tumor-derived cells,
and endothelial cells (Staton et al., 2007). In the vasculature, it is primarily expressed
on the arterial end of endothelial cells (Staton et al., 2007; Sulpice et al., 2007). NP-1
can undergo post-translational modification by the addition of glycosaminoglycan in the
linker region between b2 and c domains (Pellet-Many et al., 2008). In endothelial cells,
this modification of NP-1 enhances the VEGF/Flk-1 signaling, perhaps by stabilizing the
Flk-1 receptor and preventing its internalization and degradation (Shintani et al., 2006).
Furthermore, VEGF interaction with NP-1 is required for full activation of the Flk-1
receptor (Sulpice et al., 2008). Mutations in NP-1 results in vascular defects, including
impaired neural vascularization, defects in the great vessels, heart outflow tracts, and in
the vasculature of yolk sacs (Kawasaki et al., 1999). In addition to VEGF-A165, NP-1
can bind to VEGF-B, -E, and PLGF (Koch et al., 2011).
NP-2 was originally identified as an alternative receptor to the semaphorins
involved in axonal guidance (Kolodkin et al., 1997; Staton et al., 2007). It is expressed
in endothelial cells, primarily at the venous side as well as in lymphatic endothelial cells
(Staton et al., 2007). The receptor binds to VEGF-A165, VEGF-A145, VEGF-C, and
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VEGF-D (Soker et al., 1998; Koch et al., 2011; Staton et al., 2007). NP-2 co-localizes
and directly interacts with VEGFR-3 in lympathic vessels (Karpanen et al., 2006; Staton
et al., 2007). Defects in NP-2 result in abnormalities in lymphatic vessels and
capilliaries (Staton et al., 2007). As with NP-1, NP-2 enhances the affinity of VEGF to
Flk-1 and increases its phosphorylation (Shraga-Heled et al., 2006; Sulpice et al.,
2008).
The neuropilin receptors are involved in both physiological and pathological
angiogenesis. Neuropilins are believed to be involved in angiogenesis during the
menstrual cycle because both NP-1 and NP-2 are expressed in endothelial cells in
response to estrogen and progesterone (Staton et al., 2007). Additionally, it has been
shown that NP-1 expression is up-regulated during wound healing (Staton et al., 2007;
Matthies et al., 2002). However, it has been documented that mice which express NP-1
without its cytoplasmic domain undergo normal vasculogenesis and angiogenesis
(Fantin et al., 2011). On the other hand, the role of neuropilins has been well
documented in pathological angiogenesis. Overexpression of NP-1 resulted in
increased tumor vascular density (Miao et al., 2000; Bagri et al., 2009). NP-1 is
expressed in many human cancer cell lines (Bagri et al., 2009) with varying levels of
expression (Staton et al., 2007). In pancreatic adenocarcinoma, NP-1 and NP-2
exhibited higher mRNA expression levels than Flt-1 and Flk-1 (Fukahi et al., 2004).
Semaphorin 3A (SEMA 3A)
The semaphorin family is a group of proteins that is subdivided by class specific
domains and domain organization. These proteins are subdivied into eight classes, 1-7
and V. Classes 2, 3, and V semaphorins are secreted, and all other classes of
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semaphorins are membrane bound (Tran et al., 2007). Semaphorins are best known in
participating in both short and long range axonal cues. They mostly act as a repellent to
maintain nerve bundling, process extension, and sculpting arborization patterns (Tran et
al., 2007). Semaphorins execute their functions via the plexin receptors, which can be
divided into four classes, A-D.
In addition to axonal cues, semaphorins, particularly class 3 semaphorins,
regulate vascular development, tumor progression, metastasis, the immune response,
and platelet function (Bielenberg and Klagsbrun, 2007). SEMA 3A also modulates
blood vessel formation through the inhibition of integrin activity (Soker et al., 1998;
Acevedo et al., 2008). SEMA 3A interacts indirectly with the plexin A1 receptor, but it
requires NP-1 and NP-2 as a co-receptor to assemble the ligand-receptor complex and
cause activation (Tran et al., 2007). Little information is known on the role of plexins in
the receptor complex (Casazza et al., 2011). It has been shown that SEMA 3A disrupts
VEGF-mediated migration of endothelial cells (Miao et al., 1999; Acevedo et al., 2008).
Additionally, SEMA 3A is anti-angiogenic within the tumor vasculature (Maione et al.,
2009) and reduces the number of pericyte-coated vessels (Casazza et al., 2011).
SEMA 3A deletion leads to excess endothelial cells in the capillaries of the kidney, and
its overexpression results in the down-regulation of Flk-1 (Reidy et al., 2009). Because
VEGF and SEMA 3A share a common receptor, it is likely that SEMA 3A regulates
VEGF function. Indeed Acevedo et al. (2008) showed that SEMA 3A suppresses
VEGF-mediated angiogenesis but also acts as a permeability factor. SEMA 3A
antagonizes VEGF interaction with the neuropilin receptor and prevents the dimerization
and angiogenesis.
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The Streptozotocin (STZ) Model of Diabetes
Streptozotocin (STZ, 2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose) is
a nitrosourea analogue synthesized by Streptomycetes achromogenes and has been
used clinically as an antimicrobial and chemotherapeutic agent (Figure 1.4). In
research settings, it has also been widely used to induce insulin-dependent, or T1D.
Alloxan, another drug used to induce T1D, has been used in research settings, but
there are some differences between alloxan and STZ: (1) The selectivity of STZ on βcells is greater than alloxan; (2) the dosage range is broader in alloxan administration
than with STZ; (3) a subdiabetic dose of STZ, followed by a second identical dose leads
to increased diabetogenic activity, which is not seen with alloxan; and (4) the
diabetogenic activity of STZ is not influenced by changes in nutritional state, unlike the
activity of alloxan in which changes in sensitivity are induced by fasting or feeding
(Junod et al., 1969). Alloxan can also affect the liver by decreasing non-protein and
protein-bound sulhydryl groups, which could lead to inactivation of enzymes (Szkudelski
et al., 1998). Additionally in comparison with alloxan, STZ produces permanent
diabetes, which is ideal for T1D studies, and its use is more reproducible and better for
the induction of diabetes that is appropriate for endocrine and metabolic studies
(Karunanayake et al., 1974).
Diabetes results from beta cell toxicity and subsequent beta cell death through
necrosis (Lenzen, 2008). These events occur because STZ is transported into the beta
cells of the pancreas via the GLUT2 transporter and causes methylation of nucleic acids
and proteins (Konstantinov and Berger, 2008). The cell attempts to overcome this
damage by the activation of poly(ADP-ribose) polymerase (PARP), which then leads to
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depletion of pyridine nucleotides, nicotine adenine dinucleotide (NAD) and its reduced
form, NADH, and subsequently, ATP (Lenzen, 2008) (Figure 1.5). Additionally, there is
speculation that STZ induces diabetes through oxidative stress. STZ-induced diabetes
can also lead to an increase in nitric oxide (NO) production (Figure 1.5). NO acts as a
modulator of oxidative stress, and is also a free radical in the form of NO·. Studies have
shown that pancreatic islets have higher nitrate/nitrite levels in STZ-treated animals
versus control, and that NO had deleterious effects on the enzymes that are protective
in oxidative stress (Gonzalez et al., 2000). It has also been reported that NO-synthase
(NOS) inhibitors, such as NG-nitro-L-arginine-methyl ester (L-NAME), can lead to
attenuation of STZ-induced hyperglycemia in mice (Kolb et al., 1991). Haluzik and
Nedvidkova (2000) demonstrated that two NOS inhibitors, L-NAME and methylene blue,
were able to partially suppress the development of STZ-induced diabetes.

Figure 1.4. Chemical structure of streptozotocin.
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Streptozotocin can be injected intravenously in adult rats as well as
intraperitoneally at concentrations between 40 to 60 mg/kg or higher (Szkudelski, 2001).
There is a triphasic glucose response upon streptozotocin administration (Lenzen,
2008). During the first phase, hyperglycemia with a decrease in blood insulin is evident
within two hours of STZ administration. Beta cells exhibit morphological changes such
as intracellular vacuolization, dilation of the rough ER, decreased area of the Golgi,
reduced secretory granules and insulin content, and swollen mitochondria (Lenzen,
2008). Hypoglycemia, along with high levels of blood insulin, occurs after six hours.
The last phase is hyperglycemia and a decrease in blood insulin levels (Szkudelski,
2001).

Figure 1.5. Mechanism of STZ-induced diabetes.
STZ is able to enter the pancreatic beta-cell via the
GLUT2 transporter. It primarily induces DNA
alkylation, but can also affect proteins. This leads to
activation of PARP and subsequent reduction of
+
NAD , NADH, and ATP. Additionally, STZ is also able
to lead to an increase in nitric oxide production and
development of free radicals, which can result in DNA
damage as well.
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STZ is primarily administered via single injection; however it can be administered
with multiple injections depending on concentration. The half-life of STZ is about 15
minutes. Interestingly, beta cell necrosis begins within 24 hours after injection (Like and
Rossini, 1976). Using radiolabelling studies, Karunanayake et al. (1974) demonstrated
that after 15 minutes there was intense accumulation of STZ in the kidney and STZ liver
uptake reached its maximum at 30 minutes after injection. Thus, it seems likely that
only a small amount of STZ is required to reach the pancreas to induce its toxic effects.

Hypothesis and Specific Aims
In diabetes, BBB permeability increases. However, the mechanism of this
permeability change is not known. The goal of this project is to determine the
mechanism of the permeability increase using the streptozotocin (STZ) model of
diabetes, which is a well characterized type I model. I hypothesized that the increase in
permeability at the BBB is due to VEGF and its interaction with the Flk-1 receptor, and
subsequent activation of a signaling pathway involved in permeability. I also
hypothesized that these BBB changes can be attenuated by administration of a possible
therapeutic agent, minocycline.
Specific Aim 1: To investigate if minocycline is able to attenuate the observed
BBB changes in an STZ model of diabetes.
Specific Aim 2: To investigate the role of the VEGF signaling system as a
mechanism for the observed BBB changes.
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Chapter 2: Minocycline Decreases Blood-Brain Barrier Permeability Yet
Increases Vascular Endothelial Growth Factor in the Streptozotocin Model of
Diabetes

Abstract
Diabetes is associated with increased permeability and a decrease in tight
junction protein expression at the blood-brain barrier (BBB). There are no clinical
treatments to attenuate the BBB changes in diabetes, though several strategies have
been used in animal models. Minocycline (MIN), a tetracycline antibiotic, has antiinflammatory properties and is able to cross the BBB. Minocycline attenuates BBB
disruption via a number of proposed mechanisms including inhibition of microglia
activation, antioxidant activity, and matrix metalloproteinase inhibition. Minocycline may
protect against the previously reported changes in diabetic BBB function. This study
tests whether minocycline can attenuate the BBB changes observed in the
streptozotocin (STZ) model of diabetes. Minocycline decreased permeability and
increased expression of tight junction proteins, especially claudin-5. Furthermore,
minocycline increased protein expression of vascular endothelial growth factor (VEGF),
a potent angiogenic and permeability factor, in cerebral microvessels. Additionally,
minocycline treatment increased in protein expression of Flt-1. These results indicate
that minocycline may be a potential therapeutic agent to decrease the permeability
changes observed at the BBB in diabetes.
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Introduction
The blood-brain barrier (BBB), a semi-permeable vascular interface, is located at
the level of brain microvascular endothelial cells. The BBB regulates the CNS
extracellular environment by restricting entry from blood into brain. It allows nutrients
from the periphery to pass and mediates waste efflux from brain to blood. However, in
many pathological conditions, the barrier and its functions are compromised, which can
lead to edema and leukocyte transmigration across the barrier. These events can
activate microglia, the immune cells of the CNS, which generate immunomodulatory
molecules (Yenari et al., 2006).
In neurodegenerative diseases, such as ischemia, Parkinson’s disease, spinal
injury, multiple sclerosis, and others, treatment with minocycline, a tetracycline antibiotic
and anti-inflammatory agent, results in neuroprotection. Minocycline is of particular
interest in these diseases because it crosses the BBB and reaches therapeutic
concentrations in the brain (Zemke and Majid, 2004). Minocycline inhibits microglial
activation, and functions to decrease apoptosis and the production of reactive oxygen
species (Plane et al., 2010). Minocycline exerts its anti-inflammatory effects by
decreasing proliferation and activation of microglia, which leads to decreased release of
cytokines, matrix metalloproteinases, and other inflammatory mediators (Kim and Suh,
2009). It also inhibits transmigration of T lymphocytes (Kim and Suh, 2009).
Minocycline also has both caspase-dependent and –independent anti-apoptotic effects.
Last, minocycline is involved in signaling pathways, particularly in the inhibition of p38
MAPK activation in microglia (Hau et al., 2005). Minocycline is protective in a rat model
of ischemia (Yrjanheikki et al., 1999; Zemke and Majid, 2004). Wasserman and
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Schlichter (2007) demonstrated that administration of minocycline protected the BBB
and reduced edema after intracerebral hemorrhage. In the retina, minocycline
stimulates chemotaxis and decreases proliferation of retinal pigment epithelial cells, and
also promotes the expression of platelet derived growth factor (PDGF), hepatocyte
growth factor (HGF), vascular endothelial growth factor (VEGF), and MMP-9 (Hollborn
et al., 2010).
Diabetes is a risk factor for stroke and other cerebrovascular diseases. Clinical
studies using magnetic resonance imaging-gadolinium techniques have shown that the
BBB exhibits increased permeability (Starr et al., 2003). This permeability increase has
also been shown in the STZ model of diabetes, in conjunction with decreased tight
junction protein expression of occludin and zona occludins-1 (ZO-1) as well as an
increase in MMP-2, which may also contribute to BBB dysfunction (Hawkins et al.,
2007). The increased BBB permeability can be attenuated by therapeutic intervention
through statins (Mooradian et al., 2005) and sesamol, a natural antioxidant (VanGilder
et al., 2009).
The mechanism of this BBB permeability change, however, has not been
elucidated. Other studies using the STZ model have shown similar changes in the
blood-retinal barrier and demonstrated that VEGF plays a role in the permeability
changes (Antonetti et al., 1998). VEGF functions as a potent pro-angiogenic and
permeability factor, and its signaling system is a likely candidate for the permeability
changes occurring at the BBB. VEGF signaling occurs via its receptors, Flt-1 and Flk-1,
as well as its co-receptors, neuropilin-1 and -2 (NP-1 and NP-2) and endogenous
antagonist, semaphorin 3A (SEMA 3A). NP-1 and NP-2 enhances VEGF binding to Flt-

27

1 and Flk-1 receptors. SEMA 3A binds to the neuropilin receptors, thus inhibiting the
ability of VEGF to interact with these co-receptors. Interestingly, SEMA 3A suppresses
angiogenesis and also acts as a permeability factor through the neuropilins (Acevedo et
al., 2008). In this study, we investigate whether minocycline can attenuate the
functional and molecular changes at the BBB in the STZ model of diabetes.
Furthermore, we examined the VEGF signaling system in the diabetic brain
microvasculature, and whether minocycline has any effect on its expression.

Methods
Animal Care
Animal procedures were performed in strict accordance with the Institutional
Animal Care and Use Committee, Marshall University. Male Sprague-Dawley rats
(Hilltop Laboratories, Scottdale, PA) were injected with either 65 mg/kg STZ (Sigma, St.
Louis, MO) or 0.9% sterile saline. Seven days after STZ injection, animals were
injected with 22 mg/kg minocycline or 0.9% sterile saline twice daily for the reminder of
the study. The following conditions were maintained: 12h-12h dark-light cycle, with
ambient temperature of 22 ± 2º C, food and water given ad libitum. Animals were
euthanized 14 days after STZ injection via intramuscular injection of a 1 mL/kg cocktail
containing ketamine (71.5 mg/mL) and xylazine (5.7 mg/mL). Blood samples were
collected from the descending aorta, and tested for glucose, ketones, and lipids with an
analyzer (CardioChek PA, Polymer Technology Systems, Indianapolis, IN).
In situ perfusion
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In situ perfusion studies were performed in the laboratory of Dr. Richard Egleton
at the University of Arizona. Rats were anaesthetized with ketamine and heparinized by
intra-peritoneal injection (10,000 U/kg). The common carotid arteries were exposed
after a midline incision was made at the neck. Both arteries were cannulated, and the
jugular veins were sectioned. The brain was then perfused with an oxygenated
mammalian Ringer solution [in mM: 117 NaCl, 4.7 KCl, 0.8 MgSO4, 24.8 NaHCO3, 1.2
KH2PO4, 2.5 CaCl2, and 10 D-glucose, with 39 g/l dextran (mol wt 70,000) and 10 g/l
BSA, pH 7.4] with Evans blue at 37°C. When the desired perfusion pressure and rate of
∼100 mmHg and 3.1 ml/min was reached, [14C]sucrose (10 μCi/20 ml Ringer) was

infused via a slow-drive syringe pump (0.5 ml·min−1·hemisphere−1; model 22, Harvard

Apparatus, South Natick, MA). After a 20 minute perfusion (n = 4-6 per treatment), the
rat was decapitated and the brain was removed. Samples of the radioactive perfusate
were collected from each carotid cannula as a reference. Next, the choroid plexuses
and meninges were removed, and the cerebral hemispheres were sectioned and
homogenized. Brain tissue and 100 μl samples of perfusate were incubated for two
days in 1 ml of tissue solubizer (TS-2, Research Products, Mount Pleasant, IL) in
preparation for liquid scintillation counting. Finally, 100 μl of 30% acetic acid and 4 ml of
Budget-Solve Liquid Scintillation Cocktail (Research Products) were added, and the
samples were measured for radioactivity (model LS 5000 TD Counter; Beckman
Instruments, Fullerton, CA). Results are reported as a distribution volume (Rbr) of
radioactivity in the brain to that in the perfusate:
𝑅𝑏𝑟 =

𝑑𝑝𝑚. 𝑔−1 𝑏𝑟𝑎𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒
𝑑𝑝𝑚. 𝑚𝑙 −1 𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒
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Cerebral Microvessel Isolation
Cerebral microvessel isolation was performed as described by Hawkins et al., 2007.
After anesthetization, brain was removed and placed in a petri dish with a buffer solution
A (for 1 L: 6.02 g NaCl, 0.35 g KCl, 0.368 g CaCl2, 0.163 g KH2PO4, 0.296g MgSO4,
3.57 g HEPES, pH 7.4, 4oC). Under a dissecting microscope, meninges and choroid
plexus were removed. The cortex was dissected from brainstem and cerebellum. The
whole brain was minced and homogenized in 5 mL buffer solution B (for 1L: 6.02 g
NaCL, 0.35 g KCl, 0.368 g CaCl2, 0.163 g KH2PO4, 0.296g MgSO4, 3.57 g HEPES, 2.1
g NaHCO3, 0.11 g sodium pyruvate, 10 g dextran (~64 kDa), 1.8 g glucose, pH 7.4,
4oC). The homogenate was poured into a 50 mL tube through a 100 µm cell strainer.
The homogenate was transferred to a 30 mL centrifuge tube (Beckman Ultra-Clear), 20
mL of 26% dextran was added and spun for 10 minutes at 5800 g. After spinning, the
thick white layer at the top of tube was removed. A pale white streaky pellet on the side
of the tube remained, resuspended in 10 mL buffer solution B, and passed through a 70
µm cell strainer. The suspension was transferred to a 30 mL centrifuge tube and spun
at 500 g for 10 minutes. The supernatant was removed, and the final microvessel pellet
was resuspended in either tissue extraction buffer (ThermoScientific, Rockford, IL) for
protein extraction or TriReagent (Sigma, St. Louis, MO) for RNA isolation. Protein was
analyzed using bicinchoninic acid (BCA) protein assay kit (ThermoScientific, Rockford,
IL).
Western Blot Analysis of Immunoreactive Protein
Protein samples (20 µg/well) were separated via SDS gel electrophoresis using
4-12% Bis-Tris gel (Criterion, Bio-Rad, Hercules, CA) followed by transfer to
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nitrocellulose paper. Occludin, claudin-5, and ZO-1 antibodies were purchased from
Invitrogen, Life Technologies (Grand Island, NY). Antibodies directed against VEGF,
VEGF receptors (Flt-1, Flk-1, NP-1, and NP-2), and SEMA 3A were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) antibodies (EMD Millipore, Billerica, MA) were used to
normalize protein loading. Protein bound to each antibody was detected by horseradish
peroxidase conjugated secondary antibody (GE Healthcare Bio-Sciences, Piscataway,
NJ), and detected by the enhanced chemiluminescence system (GE Healthcare BioSciences, Piscataway, NJ).
Data Analysis
The data are reported as the mean and standard error of the mean. Statistical analysis
for all studies was via ANOVA followed by Student-Newman-Keuls analysis.

Results
Minocycline did not prevent STZ-induced changes in blood chemistry
Table 2.1 lists the selected blood chemistries of the animals in this study. There
was a significant increase in blood glucose levels in STZ-treated animals compared to
control animals, which was not affected by minocycline treatment. Both STZ groups
had high blood triglyceride levels, but animals treated with both STZ and minocycline
had a statistically significant increase in triglycerides compared to control. Figure 2.1
shows that STZ significantly reduced weight gain in the animals; however, this was not
modulated by minocycline. Additionally, there was no change in brain weights in any of
the treatment groups (Figure 2.2).
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Minocycline reversed STZ-induced increase in BBB permeability to sucrose
In situ perfusion studies (Figure 2.3) showed that STZ-treated animals had a
significant increase in BBB permeability to sucrose compared to control animals.
Treatment with minocycline lead to a significant decrease in BBB permeability to
sucrose in both control and STZ-treated animals (p<0.05, two way ANOVA, followed by
Newman-Keuls; n=6 per group).
Minocycline increased claudin-5 expression independently of STZ treatment
Western analysis showed that neither STZ nor minocycline treatment affected
ZO-1 (Figure 2.4) or occludin (Figure 2.5). Although STZ did not have an effect on
claudin-5 protein expression, treatment with minocycline resulted in a significant
increase in claudin-5 in both control and STZ-treated animals (Figure 2.6).
Minocycline increased protein expression of VEGF and Flt-1
Western analysis showed that minocycline significantly increased VEGF protein
levels in in STZ-treated animals with minocycline compared to STZ-animals treated with
saline (Figure 2.7).

There was also a significant increase in the expression of Flt-1 in

the control animals treated with minocycline compared to the saline-treated controls. A
similar trend was seen in the STZ-treated animals, though this did not reach
significance (Figure 2.8). Minocycline did not alter Flk-1 expression in diabetic rats
(Figure 2.9). Additionally, minocycline treatment had no significant effect on NP-1
(Figure 2.10) and NP-2 (Figure 2.11) protein levels in diabetic animals. The levels of
SEMA 3A protein expression were not significantly decreased with minocycline
treatment in either control or STZ-treated rats (Figure 2.12). Interestingly, there was a
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Glucose
(mg/dl)
Ketones
(mg/dl)
Triglycerides
(mg/dl)

Control +
Saline
212
(12.4)
6.93
(0.80)
58.5
(8.5)

Control +
Minocycline
219
(13.5)
6.99
(1.44)
53.0
(3.0)

STZ +
Saline
453
(35)**
13.07
(2.69)
98.3
(21.9)

STZ +
Minocycline
427
(37)**
13.31
(2.20)
137
(23.4)**

Table 2.1. Blood chemistries of control and diabetic animals treated with
minocycline. STZ treatment significantly increased blood glucose (**p<0.05, two-way
ANOVA followed by Student-Newman-Keuls). Minocycline had no effect on diabetes
since it did not prevent the STZ-induced increase in blood glucose. Ketones and
triglycerides were elevated in STZ groups. (n=8 for Control + Saline; n=9 for Control +
Minocycline; n=10 for STZ + Saline; n=9 for STZ + Minocycline)
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Figure 2.1. Minocycline did not prevent weight loss in STZ-treated animals. STZ
treatment significantly reduced body weight in the animals (p<0.01 compared to control,
two-way ANOVA followed by Student-Newman-Keuls, n=10-14 per group). Treatment
with minocycline had no effect on body weight.
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Figure 2.2. No effect of STZ or minocycline on brain weight. Treatment with STZ
or minocycline did not affect whole brain weights in the animals. (n=5 for CON +SAL
and STZ+ MIN; n=4 for CON+ MIN and STZ +SAL).
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Unidirectional transfer constant (Kin) for sucrose
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Figure 2.3. Minocycline reversed STZ-induced increase in BBB permeability. STZ
significantly increased BBB permeability to sucrose. Treatment with minocycline
significantly reduced permeability of the BBB to sucrose in both control and STZ-treated
animals (p<0.5, two-way ANOVA followed by Newman-Keuls, n=6 per group). Data for
this figure were gathered at the University of Arizona by Dr. Egleton under his radiation
license for that institution.
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Figure 2.4. No effect of STZ or minocycline on ZO-1. Neither STZ nor
minocycline had an effect on ZO-1 protein levels. The positive (+) sign
indicates treatment with STZ or minocycline, and the negative (-) indicates
no STZ or minocycline treatment. (n=5 for CON +SAL and STZ+ MIN; n=4
for CON+ MIN and STZ +SAL).
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Figure 2.5. No effect of STZ or minocycline on occludin. No change was
observed in occludin in any treatment. The positive (+) sign indicates treatment
with STZ or minocycline, and the negative (-) indicates no STZ or minocycline
treatment. (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and STZ
+SAL).
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Figure 2.6. Minocycline treatment increased claudin-5. There was a
significant increase in claudin-5 protein levels in both control and STZ groups
treated with minocycline compared to their corresponding controls (*p<0.05,
two-way ANOVA followed by Student-Newman Keuls). The positive (+) sign
indicates treatment with STZ or minocycline, and the negative (-) indicates no
STZ or minocycline treatment. (n=5 for CON +SAL and STZ+ MIN; n=4 for
CON+ MIN and STZ +SAL).
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shift in the ratio of VEGF to SEMA 3A, indicating that in the minocycline-treated rats
there should be an increase in VEGF signaling (Figure 2.13).
Discussion
The goal of this study was to determine whether minocycline could attenuate the
previously reported changes in BBB changes permeability to sucrose in the STZ model
of diabetes. Additionally, we investigated the effects of minocycline on VEGF and its
receptors at the BBB. To our knowledge, this is the first study to show that minocycline
is able to decrease BBB permeability to sucrose in a rat model of diabetes and increase
protein expression of tight junction proteins. Treatment with minocycline alters the
protein expression of VEGF and some components of its signaling pathway, implicating
this signaling system in the response to minocycline treatment.
BBB integrity is compromised in diabetes. Clinical studies demonstrated that
there is an increase in permeability to gadolinium-DTPA at the BBB in diabetic patients
(Starr et al., 2003). This finding has been supported by others using animal models. In
the STZ model of diabetes, an increase of various markers for paracellular permeability
have been reported including [14C] sucrose (Huber et al., 2006; Hawkins et al., 2007)
and dextrans of varying molecular weights (Mooradian et al., 2005). This increase in
BBB paracellular permeability has been linked to decreased tight junction protein
expression, in particular occludin (Hawkins et al., 2007). In our study we also report
that STZ-induced diabetic animals exhibited a significant increase in permeability to
sucrose compared to control animals. This result correlates well with the previous
studies by our group and others (Huber et al., 2006; Hawkins et al., 2007). In the STZ
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animals that were treated with minocycline, the permeability to sucrose was significantly
reduced compared to the saline-treated STZ animals (Figure 2.3). BBB permeability in
minocycline-treated diabetic animals was not different from control (Figure 2.3). This
result complements other studies that used minocycline to inhibit BBB permeability
changes (Nagal et al., 2008; Wasserman and Schlichter, 2007). Interestingly however,
the permeability of the control animals to sucrose was also reduced, indicating that
minocycline effect was not necessarily related to an inhibition of something specific to
the STZ model. Further, minocycline did not have a significant effect on the diabetic
status of the animals (Table 1).
Changes in sucrose permeability are often linked with changes in tight junction
protein expression. Western analysis showed no change in either ZO-1 or occludin
protein expression in control and diabetic animals, though the occludin was mildly
decreased. This result is different from our previous studies, in which we showed both
ZO-1 and occludin decrease at the same time point (Hawkins et al., 2007). Protein
expression of claudin-5 did not change in the diabetic animals. However, treatment with
minocycline significantly increased protein expression of claudin-5 in both control and
STZ-treated animals (Figure 2.6). It has been suggested that claudins act as a primary
seal for the tight junctions while occludin is present as a support structure (Hawkins and
Davis, 2005). Therefore, the “tighter” junction induced by minocycline may be via an
increase in claudin-5. To our knowledge this effect of minocycline has not been
reported previously. Most studies only give a small number of doses, and the animals in
this study were given minocycline twice a day for seven days. Previous studies have
shown that if the levels of claudin-5 are increased, then there will be a decrease in the
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Figure 2.7. Minocycline stimulated VEGF expression in STZ-treated
animals. Western analysis showed there was a significant difference
between treatment groups (saline vs. minocycline, p<0.05, two-way ANOVA
followed by Student-Newman-Keuls). There was a significant increase in
VEGF protein levels in STZ-induced diabetic animals treated with minocycline
(*p<0.05, two-way ANOVA followed by Student-Newman-Keuls). A similar
trend was observed in control animals treated with minocycline. The positive
(+) sign indicates treatment with STZ or minocycline, and the negative (-)
indicates no STZ or minocycline treatment. (n=5 for CON +SAL and STZ+
MIN; n=4 for CON+ MIN and STZ +SAL).
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Figure 2.8. Minocycline increased Flt-1 expression in control animals.
Western analysis showed that there was a significant difference between treatment
groups (saline vs. minocycline, p<0.05, two-way ANOVA followed by StudentNewman-Keuls). There was a significant increase in Flt-1 protein expression in
control animals treated with minocycline (* p<0.05, two-way ANOVA followed by
Student-Newman-Keuls). No change was observed in STZ-treated animals upon
minocycline treatment. The positive (+) sign indicates treatment with STZ or
minocycline, and the negative (-) indicates no STZ or minocycline treatment. (n=5
for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and STZ +SAL).
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Figure 2.9. Minocycline did not have an effect on Flk-1. Treatment with STZ or
minocycline did not have an effect on Flk-1 protein expression (two-way ANOVA
followed by Student-Newman Keuls). The positive (+) sign indicates treatment
with STZ or minocycline, and the negative (-) indicates no STZ or minocycline
treatment. (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and STZ +SAL).
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Figure 2.10. Minocycline did not affect NP-1 expression. No significant changes
were observed in NP-1 protein levels with STZ or minocycline treatment (two-way
ANOVA followed by Student-Newman-Keuls). The positive (+) sign indicates
treatment with STZ or minocycline, and the negative (-) indicates no STZ or
minocycline treatment. (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and
STZ +SAL).
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Figure 2.11. No effect of minocycline on NP-2 expression. No significant changes
were observed in NP-2 protein levels with either STZ or minocycline treatment (two
way ANOVA followed by Student-Newman-Keuls). The positive (+) sign indicates
treatment with STZ or minocycline, and the negative (-) indicates no STZ or
minocycline treatment. (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and
STZ +SAL).
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Figure 2.12. Minocycline did not affect SEMA 3A. Western analysis
showed that there was no significant change in SEMA 3A protein levels with
either STZ or minocycline treatment (two-way ANOVA followed by StudentNewman-Keuls). The positive (+) sign indicates treatment with STZ or
minocycline, and the negative (-) indicates no STZ or minocycline treatment.
(n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and STZ +SAL).
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Figure 2.13. Minocycline increased the VEGF:SEMA 3A ratio.
Western analysis showed that there was no statistically significant change
in VEGF:SEMA 3A ratio. Although, there appears to be a trend in an
increase of VEGF:SEMA 3A with minocycline in both control and STZtreated animals. (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN
and STZ +SAL).
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permeability of tight junctions (Feliniski et al., 2008; Kashiwamura et al., 2011). Thus
the decrease in permeability seen in this study is consistent with an increased claudin-5
expression. Claudin-5 is known to be regulated via a number of different mechanisms.
The tight junctions are highly dynamic structures with a constant recycling of barrier
proteins from the junctional domain to either storage or lysosomal components (Utech
et al., 2010; Stamatovic et al., 2011; Dukes et al., 2012). Claudin-5 has been reported
to be associated with caveolin-1, and its removal from the junctional complex to a
caveolin-1-rich microdomain is associated with an opening of tight junctions (Nag et al.,
2007; Stamatovic et al., 2011). Multiple post-translational modifications, such as
phosphorylation and ubiquitination, of claudin-5 are associated with its recycling.
Ubiquitination of claudin-5 appears to trigger the ubiquitin-proteasome system, leading
to degradation, partially via a lysosomal-mediated manner (Mandel et al., 2012).
Inhibition of this ubiquitination leads to an increase in the levels of claudin-5. Therefore,
it is possible that minocycline is inhibiting the recycling of claudin-5 from the membrane
and/or its ubiquitination in both the control and STZ-treated animals. The half-life of
claudin-5 has been reported to be 70-90 minutes (Mandel et al., 2012). In minocyclinetreated control and STZ-treated animals, the inhibition of claudin-5
recycling/degradation could lead to a gradual increase in the levels of claudin-5 and a
decrease in BBB permeability.
The role of minocycline in regulating this BBB permeability/claudin-5 is potentially
via a combination of mechanisms. Minocycline is also known to inhibit MMPs, which
have been reported to degrade several tight junction proteins including claudin-5. In a
recent study, doxycycline (a related tetracycline) prevented claudin-5 loss during a
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short-term treatment strategy following MCAO, and the mechanism was proposed to be
via a reduction in MMP activity (Wang et al., 2012). In our model, we were looking at a
long term treatment with minocycline (7 days), and observed an increase in control
levels of claudin-5. A previous study reported an increase in MMP activity in our STZtreated animals (Hawkins et al., 2007). The control animals also had a small, yet
measureable, baseline activity of MMP activity (Hawkins et al., 2007). Therefore, it is
possible that the MMP is involved in the basal turnover of claudin-5, and the inhibition of
this may contribute to the accumulation of claudin-5.
Another mechanism in which minocycline could promote claudin-5 is via
inhibition of PKC. PKC activation has been shown in several cell types to alter the
distribution of claudins (Sjo et al., 2010). Hence, it is possible that part of the recycling
mentioned earlier is PKC-dependent. In fact, PKC-α has been shown to play an
important role in caveolin-based endocytosis (Sharma et al., 2004). As a known
inhibitor of PKC-α, minocycline could inhibit claudin-5 recycling via this mechanism
(Nikodemova et al., 2007), thus promoting a buildup of claudin-5 and reduced sucrose
permeability.
VEGF has also been linked to not only BBB function, but also claudin-5
regulation (Argaw et al., 2009). Furthermore, VEGF has been linked to the tight junction
dys-regulation in diabetes as well as diabetic-induced endothelial dysfunction
(Murakami et al., 2012). VEGF is involved in angiogenesis and increased permeability,
and is a likely candidate for involvement in the observed BBB permeability changes in
diabetes. Thus, we investigated the role of VEGF in STZ- and minocycline-induced
changes in claudin-5.
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Western analysis demonstrated that VEGF protein levels decreased in STZtreated diabetic rats. Minocycline increased VEGF protein expression in both control
and STZ-treated rats, with significance in the latter group. This result is opposite to
what we expected based on studies in the retina. Harhaj et al. (2006) showed elevated
VEGF-induced changes in tight junction proteins leads to increased permeability, and
reduced VEGF prevents the permeability change. Isoforms of VEGF can be diffusible
or bound to the extracellular matrix. VEGF165, the most studied isoform, is secreted but
the majority is bound to the extracellular matrix (Ferrera et al, 2003). Hollborn et al.
(2010) demonstrated that minocycline promoted the expression of VEGF in retinal
pigment epithelial cells. Wasserman and Schlichter (2007) showed that minocycline
decreased MMPs at the BBB, likely keeping the extracellular matrix relatively intact.
Therefore, the inhibition of MMPs reduced the VEGF release from the basement
membrane, perhaps explaining the increased levels of VEGF. It is also important to
remember that VEGF response is due to the interaction of a number of receptors and
cofactors. Thus, we looked at expression levels of the primary VEGF receptors and its
inhibitory cofactor, SEMA 3A.
At the BBB, VEGF has two primary receptors and two co-receptors. The
interaction of the VEGF receptors, Flt-1 and Flk-1, with the neuropilin receptors dictates
the cellular response induced by VEGF. In our study, STZ did not have an effect on the
VEGF receptors, Flt-1 and Flk-1. However, minocycline significantly increased protein
expression of Flt-1 in control animals and showed a similar trend in the STZ-treated
animals. Minocycline also increased protein expression of Flk-1 in the control group,
but it did not have an effect on the receptor in STZ-treated animals. Minocycline had no
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significant effect on expression of the neuropilin receptors, NP-1 and NP-2, in either
control or STZ groups. Finally, the VEGF regulator, SEMA 3A, was decreased in both
control and STZ-treated animals, although not statistically significant.
VEGF-induced angiogenesis and permeability are regulated by a complex
interaction of receptors, predominantly Flk-1 and the neuropilin receptors. It has been
proposed that the ratio of VEGF to SEMA 3A is a critical factor in driving permeability.
Although not significant, we see a decrease in VEGF in the STZ-treated animals. This
decrease in VEGF would promote the SEMA 3A portion of the response, which is linked
to an increase in permeability (Acevedo et al., 2008; Le Guelte et al., 2012). This
observation could explain the change in STZ-induced permeability. Le Guelte et al.
(2012) showed that this change is in part due to inhibition of serine phosphatase PP2A
activity promoting a dissociation of VE-cadherin from adherens junctions. An increase
in Flt-1 and no change in Flk-1 in diabetic rats with minocycline treatment suggests that
the “decoy receptor,” Flt-1, may be sequestering any VEGF that might be secreted,
inhibiting its ability to bind to the Flk-1 receptor, which has the major role in inducing
changes at tight junctions. Previous studies have demonstrated that minocycline is able
to decrease VEGF-induced smooth muscle cell migration in the vasculature by
downregulating the Erk 1/2 and PI3K/Akt signaling pathways (Yao et al., 2004, 2007).
VEGF is able to bind to the neuropilin receptors, and its binding enhances its ability to
bind to and activate Flk-1 (Sulpice et al., 2008).

Last, minocycline decreased protein

expression of the VEGF antagonist, SEMA 3A, in both control and STZ-treated animals,
although not significant. On its own, SEMA 3A is also a permeability factor (Acevedo et
al., 2008).

Lower SEMA 3A levels due to minocycline treatment would result in greater
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VEGF binding to neuropilin receptors, and consequently, smaller BBB permeability
changes than normally in diabetic animals.
In conclusion, our study shows that minocycline is able to decrease permeability
to sucrose, a low molecular weight molecule, in diabetic microvessels. This
permeability decrease coincides with an increase in protein expression of claudin-5.
Minocycline is able to increase protein expression of VEGF in the diabetic group. No
change was observed in the Flk-1 receptor, but the Flt-1 receptor increased. This
increase in receptor expression suggests that VEGF is sequestered by Flt-1, and is
prevented from binding Flk-1. Thus, it is likely that the Flk-1 is not phosphorylated and
subsequently, any signaling pathway that would lead to a permeability increase is not
activated. Although the protein expression of the neuropilin receptors increased in the
diabetic group treated with minocycline, VEGF signaling is unlikely since there was no
change in Flk-1. Last, minocycline decreased protein expression of SEMA 3A, but not
significantly. It is possible to reduce permeability in diabetic microvessels through this
route as well. Therefore, minocycline is a potential therapeutic treatment for decreasing
permeability at the BBB in diabetes.
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Chapter 3: The Potential Role and Regulation of VEGF in BBB Dysfunction
Abstract
Diabetes is characterized by hyperglycemia, which can lead to various
macrovascular and microvascular complications. Microvascular complications are
evident in retinal and renal pathologies. Similar complications are evident in the brain
microvasculature particularly in the blood-brain barrier (BBB), a specialized
microvasculature composed of endothelial cells that interacts with various cell types in
the brain. Significant changes to the BBB occur in diabetes; however, the mechanisms
leading to these changes are unknown. This study focuses on the vascular endothelial
growth factor (VEGF) signaling system, a potent pro-angiogenic and vascular
permeability factor, as a potential mechanism for the observed BBB changes.
Previously, we have shown a potential role of VEGF-based signaling for the observed
BBB changes (Chapter 2). In the present study, results showed changes in mRNA of
VEGF and its receptors; however VEGF protein levels remained unchanged in diabetic
animals. Interestingly, protein expression of VEGF receptors and co-receptors as well
as SEMA 3A, an antagonist of VEGF, did not change. In this study, we investigated
the possibility that altered abundance of microRNAs (miRNAs) might explain the
discrepancy between our mRNA and protein data. Protein expression of PLC-γ, a
downstream signaling target of Flk-1, showed statistically significant changes within the
diabetic groups. Taken together, these results indicate that VEGF signaling could be
based on the relative diabetic state as a result of the absence of insulin or other
changes that occurred as a consequence of STZ toxicity.
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Introduction
Diabetes is a risk factor for vascular dementias and cardiovascular events such
as stroke. The exact mechanism behind the increased risk is unknown; however it is
often linked with hyperglycemia and subsequent cerebral edema. Increased peripheral
vascular permeability and the development of vascular complications contribute to the
morbidity and mortality of diabetes (Perrin et al., 2009). There is now increasing
evidence that the cerebral blood vessels are also compromised, and that this may
contribute to the neurological problems associated with diabetes (Huber et al., 2006).
Under normal circumstances brain homeostasis is regulated by the blood-brain barrier
(BBB). The BBB, a specialized microvascular structure comprised of endothelial cells
held together by tight junctions, functions to protect the brain from toxins in the
peripheral circulation, to allow nutrients to move from blood to brain, and to mediate
waste efflux from the brain (Hawkins and Davis, 2005). Overall, the BBB is important
for the maintenance of the central nervous system. Breakdown of the BBB can lead to
changes in cognition and poor cardiovascular outcomes (Huber et al., 2006).
Clinical studies have shown that diabetic patients have increased permeability of
the BBB (Starr et al., 2003). This permeability increase has been observed in
experimental models of diabetes and has been associated with a decreased expression
of tight junction proteins, particularly occludin and ZO-1 (Hawkins et al., 2007). The
change in permeability can be prevented by insulin acutely (Hawkins et al., 2007; Huber
et al., 2006), but not chronically (Huber et al., 2006), and by using seasmol (VanGilder
et al., 2009) or minocycline (Chapter 2). Several factors have been linked to these
changes including increased matrix metalloproteinase activity (Hawkins et al. 2007),
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dyslipidemia (Ginsberg, 1999; Goldberg, 2001), and reactive oxygen species (VanGilder
et al., 2009). However, the exact mechanism of these changes is unknown. Similar
changes in tight junction expression at the blood-retinal barrier have been shown to be
regulated by VEGF (Antonetti et al., 1998).
The VEGF family consists of dimeric glycoproteins VEGF-A, -B, -C, -D, and
placental growth factor (Olsson et al., 2006). VEGF-A, the main and most studied, has
several isoforms, with VEGF165 being the most abundant (Wirostko et al., 2008). VEGFA is a modulator of both angiogenesis and permeability. It exerts its effects by binding
to membrane bound VEGF receptors-1 and -2 (Flt-1 and Flk-1, respectively) as well as
the neuropilin receptors-1 and -2 (NP-1 and NP-2). Flt-1 is thought to be a decoy
receptor regulating VEGF/Flk-1 interaction, whereas Flk-1 regulates permeability in the
kidney and eye as well as directly transmitting signals associated with pathological
angiogenesis (Wirostko et al., 2008). The binding of VEGF to the Flk-1 receptor can
result in activation of several pathways leading to increased permeability, survival,
migration, and proliferation (Holmes et al., 2007). For stimulation of angiogenesis,
simultaneous binding of VEGF to both Flk-1 and NP receptors is required (Sulpice et al.,
2008). This interaction can be blocked by SEMA 3A, which binds to the NP receptors
thereby blocking the VEGF binding site. The presence of SEMA 3A does not however
affect VEGF-induced permeability changes, but there is also evidence that SEMA 3A
can induce permeability on its own (Acevedo et al., 2008).
Previous studies have shown that the BBB is sensitive to VEGF (Fischer et al,
2004; Argaw et al, 2009). I hypothesized that VEGF signaling is also involved in BBB
breakdown in diabetes. We used an experimental model of diabetes to investigate
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regulation of the VEGF signaling system at the BBB using real-time PCR, ELISA, and
immunoblot techniques, and miRNA studies.

Methods
Animal Care
Animal procedures were performed in strict accordance with the Institutional Animal
Care and Use Committee, Marshall University. Male Sprague-Dawley rats (Hilltop
Laboratories, Scottdale, PA) were injected with either 65 mg/kg STZ (Sigma, St. Louis,
MO) or 0.9% sterile saline. Animals were maintained under a 12h-12h dark-light cycle,
at ambient temperature of 22 ± 2o C, with food and water available ad libitum. Animals
were euthanized 14 days post-injection via an intramuscular injection of 1 mL/kg of a
cocktail containing ketamine (71.5 mg/mL) and xylazine (5.7 mg/mL). Blood samples
were collected from the descending aorta and tested for glucose, ketones, and lipids
with an analyzer (CardioChek PA, Polymer Technology Systems, Indianapolis, IN). The
blood samples were centrifuged and plasma samples were stored at -80°C. Diabetic
rats were divided into groups based on their blood glucose levels: mild ≥ 300 mg/dl and
high ≥ 400 mg/dl.
Cerebral Microvessel Isolation
Microvessels were isolated from rat brains as previously described (Hawkins et al,
2007). The final microvessel pellet was resuspended in either tissue extraction buffer
(ThermoScientific, Rockford, IL) for protein extraction or TriReagent (Sigma, St. Louis,
MO) for RNA isolation. Protein was analyzed using bicinchoninic acid (BCA) protein
assay kit (ThermoScientific, Rockford, IL).
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Reverse Transciption and Real-time Polymerase Chain Reaction
RNA was isolated via TriReagent following the manufacturer’s protocol (Sigma, St.
Louis, MO), and samples were incubated with the complete reaction mixture from the
iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA) to obtain cDNA. Then cDNA was
incubated with a reaction mixture containing iQ SYBR Green Supermix (Bio-Rad,
Hercules, CA) and the appropriate forward and reverse primers of each gene listed in
Table 3.1 (Invitrogen, Carlesbad, CA).
ELISA
Rat VEGF ELISA kits were purchased from RayBiotech, Inc (Norcross, GA). All
reagents and samples were brought up to room temperature prior to use. Solutions,
standards and samples were prepared as per protocol instructions.
Western Blot Analysis of Immunoreactive Protein
The levels of specific proteins were identified by Western blot analysis. Protein samples
(20 µg/well) were separated via SDS gel electrophoresis using 4-12% Bis-Tris gel
(Criterion, Bio-Rad, Hercules, CA) followed by transfer to nitrocellulose paper. Western
blot analysis was performed using primary antibodies directed against VEGF, Flk-1, Flt1, and p-Flk-1 (Tyr 951,1175, and 1214), NP-1, NP-2, and SEMA 3A (Santa Cruz
Biotechnology, Santa Cruz, CA). Antibodies directed against p-PI3K, PI3K, p-Akt, Akt,
p-PLCγ, PLCγ, p-Erk 1/2, Erk 1/2, p-Src, Src, p-p38, and p38 were purchased from Cell
Signaling Technology (Danvers, MA). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) antibodies were used to normalize protein loading. The presence of protein
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bound to each antibody was detected by horseradish peroxidase conjugated secondary
antibody (GE Healthcare Bio-Sciences, Piscataway, NJ). Protein bands were detected
by the enhanced chemiluminescence system (GE Healthcare Bio-Sciences,
Piscataway, NJ).
Extraction and Purification of microRNA (miRNA)
A PreAnalytiX’s PAXgene® Blood miRNA Kit was used to extract the miRNA from blood
samples from control and STZ animals. Approximately 200 ng of miRNA was reverse
transcribed to cDNA using Qiagen RT2 miRNA First Strand Kit. Because over 300
miRNAs have been identified in rats, Qiagen MAR-3100G miRNA 384 arrays was used
to run each assay. BioRAD iQTM SYBR® Green Supermix and RNAse-free water plus
sample were used for the arrays. Ct values were obtained after the data was analyzed
on the ROCHE-480 Light Cycler using the Absolute Quantitative/2nd Derivative Max
program. Fold change data was analyzed using the SA Bioscience’s RT2 miRNA PCR
Array Data Analysis program. Both Rnu6 and miR-16 were used as housekeeping
genes. Statistical analyses were performed using student’s t-test. Fold change >3.0
and <0.3 was used as cut-off for miRNAs up- or down-regulated respectively, and
P<0.05 was used to indicate significance.
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Primer

Sequence (5’→3’)

VEGF

GCCAGCACATAGGAGAGATGAGC Forward

VEGF

CAAGGCTCACAGTGATTTTCTGG

Reverse

Flt-1

AGGAGAGGACCTGGAACTGTCTT

Forward

Flt-1

ATTCCTGGGCTCTGCAGGCATAG

Reverse

Flk-1

TAGCACGACAGAGACTGTGAGG

Forward

Flk-1

TGAGGTGAGAGAGATGGGTAGG

Reverse

NP-1

GGAGCTACTGGGCTGTGAAG

Forward

NP-1

ATGTCGGGAACTCTGATTGG

Reverse

NP-2

ACACAAGGAGCCATTTCCAG

Forward

NP-2

CGGATCCTGATGAAACGAGT

Reverse

SEMA 3A

AAGGCCGGGCACTCTCAAG

Forward

SEMA 3A

ACTCCTGGGTGCCCTCTCAACT

Reverse

GAPDH

TCCACCACCCTGTGCTGTA

Forward

GAPDH

ACCACAGTCCATGCCATCAC

Reverse

Forward/Reverse

Table 3.1. Primers used for Real-Time PCR experiments
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Results
Blood Chemistries
Table 3.2 shows blood characteristics and weights of control and diabetic animals.
Blood glucose levels were significantly different in diabetic animals compared to
controls. These differences in blood glucose levels within the diabetic group prompted
us to separate this group into mild and high glucose groups for subsequent
experiments. Ketone levels were significantly different between the diabetic groups as
well as between control and high glucose animals. Cholesterol, HDL, and triglyceride
levels remained relatively unchanged in both control and diabetic animals. Weight was
significantly lower in animals with mild and high glucose levels at 7 and 14 days postinjection compared to control (Table 3.3).
STZ treatment increased VEGF and VEGF receptor mRNA expression
To determine mRNA expression of VEGF and the VEGF receptor system, RNA from
both control and STZ-treated rats was isolated (Figure 3.1). Real-time PCR showed
that mRNA expression of VEGF increased about 2.5 fold in the microvessels of STZtreated animals compared to control. Additionally, expression of the VEGF receptors,
Flt-1 and Flk-1, as well as the neuropilin receptors, NP-1 and NP-2, increased in
diabetic rats. SEMA 3A mRNA expression also increased in diabetic rats compared to
control.
VEGF protein levels remain unchanged
To determine whether VEGF levels changed in diabetic versus control rats, protein from
microvessels were isolated. ELISA analysis (Figure 3.2A) showed that there was no
change in VEGF protein levels in the microvessels of STZ-treated animals. Additionally,
plasma levels of VEGF did not change in diabetic animals versus control (Figure 3.2B).
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Western analysis showed no appreciable change in VEGF in animals with mild or high
glucose compared to control animals (Figure 3.3).
VEGF receptor protein levels did not exhibit glucose-dependent changes
Western analysis showed that protein levels of the VEGF receptors, Flt-1(Figure 3.4)
and Flk-1 (Figure 3.5), did not change in the diabetic groups compared to control.
Additionally, the co-receptor, NP-1 did not change in all the groups (Figure 3.6). The
VEGF modulator SEMA 3A, which competitively binds to the neuropilin receptors,
remained relatively unchanged in diabetic animals compared to control (Figure 3.7).
Circulating MicroRNA changes in diabetes
MicroRNA studies showed an up-regulation of miR-330, -26b, -361, -139-5p, and let-7a
and let-7c, and a down-regulation in miR-127 and -497. These miRNAs are involved in
insulin signaling as well as VEGF and its receptors (Table 3.4).
No change in Flk-1 phosphorylation
To determine whether the Flk-1 receptor was activated, we looked at three
phosphorylation sites, tyrosine 951, 1175, and 1214, on the receptor that regulates the
downstream signaling of VEGF. Western analysis showed no changes in
phosphorylation (Figures 3.8-3.10).
Regulation of downstream targets of Flk-1
To determine if the observed changes at the BBB was due to the activation of Flk-1, we
examined downstream signaling targets at the three phosphorylation sites.
Phosphorylation of 951 leads to activation of Src, which can subsequently lead to a
permeability increase (Holmes et al., 2007). However, in our animal model, expression
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Glucose
(mg/dL)
264
358*

Ketones
(mg/dL)
8.8
17*

Cholesterol
(mg/dL)
100
126

Control
Mild
Glucose
High
487*
16*
110
Glucose
* Kruskal-Wallis One-Way ANOVA on Ranks p=<0.001
compared to control
† Kruskal-Wallis One-Way ANOVA on Ranks p = 0.021
compared to control
†† Kruskal-Wallis One-Way ANOVA on Ranks p = <0.001
compared to control
‡ Kruskal-Wallis One-Way ANOVA on Ranks p = 0.025
compared to control

HDL

Triglycerides

26
44†

87
177

39††

152‡

Table 3.2. Blood chemistry of control and diabetic animals. (n=15 for control; n=9 for
mild glucose; n=6 for high glucose)
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Day 1 (g)

Day 7 (g)

Day 14 (g)

Control

329

368

389

Mild Glucose

324.5

320*

317‡

High Glucose

327

313†

306††

* Kruskal-Wallis One-Way ANOVA on Ranks p = <0.001
compared to control
† One-Way ANOVA p = <0.001 compared to control
‡ Kruskal-Wallis One-Way ANOVA on Ranks p = <0.001
compared to control
†† Kruskal-Wallis One-Way ANOVA on Ranks p = <0.001
compared to control
Table 3.3. Weights of control and STZ-induced diabetic animals during the 14day time course. (n=15 for control; n=9 for mild glucose; n=6 for high glucose)
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of Src did not show any change (Figure 3.11). Phosphorylation at tyrosine 1175 can
result in either phosphorylation of PI3K, which leads to increased permeability, or
phosphorylation of PLCγ, which results in changes in gene transcription and
subsequent proliferation of endothelial cells (Holmes et al., 2007). Our studies showed
that total phosphorylation expression of PI3K or its downstream target, Akt, did not
exhibit any change (Figures 3.12-3.13). Interestingly, the ratio of p-PLCγ/PLCγ showed
a statistically significant decrease between diabetic animals with high glucose (Figure
3.14), but phosphorylation expression of Erk 1/2, the downstream target of PLCγ, did
not significantly change (Figure 3.15). Phosphorylation of Flk-1 at tyrosine 1214 can
lead to the activation of p38 MAPK to induce actin reorganization and migration of
endothelial cells (Holmes et al., 2007); however, our studies did not show any change in
p38 protein expression (Figure 3.16).

Discussion
Increased BBB permeability has been observed in both clinical studies and in animal
models of diabetes. However, the mechanism of this permeability increase has not
been elucidated. Studies have shown that VEGF is a modulator of blood-retinal barrier
permeability in a diabetic model of diabetes (Antonetti et al., 1998). The present study
focuses on VEGF as a modulator of BBB permeability due to its capability to act as a
pro-angiogenic and permeability factor. To determine if VEGF is involved in the
observed changes in the BBB in diabetes, we initially looked at gene expression of
VEGF and its receptors via real-time quantitative PCR. Our results show that gene
expression of VEGF, its receptors, and SEMA 3A increased in diabetic rats compared to
control. However, when protein expression was evaluated, there was no change in
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VEGF levels in diabetic animals with mild or high glucose compared to the control
group. Microvessel-based VEGF can be found in two main locations: 1) within the cell
itself or 2) sequestered in the matrix of the basement membrane, where it is bound via
its heparin binding domain (Zhang et al., 2009) to glycosaminoglycan chains and other
components of the extracellular matrix (Gabhann et al., 2009). Under normal
circumstances VEGF-A165 is synthesized by the cell and then released into the
extracellular matrix. Under conditions which promote basement membrane breakdown,
VEGF is rapidly released allowing for repair. Basement membrane disruption is a
common feature in BBB breakdown, mediated via an elevation in MMP activity. We
have previously reported BBB breakdown in the STZ model paralleled by an increase in
MMP activity (Hawkins et al., 2007). It is thus possible that if extra VEGF is being
made, it is being released at a rate that equals the rate of production, potentially via
MMP-induced basement membrane degradation. In fact, though not significant, there
was a ~15% decrease in the levels of microvessel-related VEGF in the STZ animals.
Typically, a pathological event will up-regulate VEGF and its receptors. Protein
expression of the VEGF receptors, Flt-1 and Flk-1, and the co-receptor, NP-1, did not
change in the diabetic groups compared to control. There are potential mechanisms
that might shed light to this observation. VEGF and its receptors have been shown to
increase during pathological events. On the other hand, VEGF has also been shown to
down-regulate receptor expression, despite an increase in receptor mRNAs (Wang et
al., 2000). Additionally, it is possible that receptors are being either degraded or
sequestered into the cell. Studies have demonstrated that VEGF stimulation was able

66

6

5

Fold Change

4

Control
STZ

3

2

1

0
VEGF

Flk-1

Flt-1

NP-1

NP-2

SEMA 3A

Figure 3.1. Real-time PCR analysis. Gene expression of VEGF, its receptors, coreceptors, and SEMA 3A increased in STZ-induced diabetic animals compared to
control (n=5).
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Control

STZ

Figure 3.2. ELISA analysis of VEGF protein levels in cerebral
microvessels and plasma of control and diabetic animals. VEGF
protein levels did not change in (A) microvessels or (B) plasma of either
control or diabetic animals. (n=23 for microvessels; n=8 for plasma)
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Control

Mild

High
VEGF 15 kDa

GAPDH 37 kDa

Percent Average to Normalized Control

200
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100

50

0
Control

Mild

High

Figure 3.3. VEGF protein levels did not change in diabetic animals.
VEGF protein levels did not change in diabetic animals with mild or high
glucose levels compared to control. (one-way ANOVA; n=12 for control; n=8
for mild; n=4 high)
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Control

Mild

High
Flt-1 180 kDa
GAPDH 37 kDa

Percent Average of Normalized Control
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100

50

0
Control

Mild

High

Figure 3.4. Flt-1 protein expression did not change. Western analysis
showed that Flt-1 protein expression did not change in diabetic animals with
mild or high blood glucose levels compared to control animals. (one-way
ANOVA; n=11 for control; n=6 for mild; n=5 for high)

70

Control
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High
Flk-1 150 kDa
GAPDH 37 kDa

Percent Average of Normalized Control
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Figure 3.5. Flk-1 protein expression did not change diabetic animals.
There was no change in Flk-1 protein levels in diabetic animals with mild or
high blood glucose levels compared to control animals. (one-way ANOVA;
n=14 for control; n=9 for mild; n=5 for high)
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Figure 3.6. No change in NP-1 expression in diabetic animals. No change
was observed in NP-1 protein levels in diabetic animals with mild or high blood
glucose levels compared to control animals. (one-way ANOVA; n=10 for
control; n=5 for mild; n=5 for high)
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Control
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GAPDH 37 kDa

Percent Average of Normalized Control
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Figure 3.7. No change in SEMA 3A expression. Western analysis showed
no change SEMA 3A protein levels in diabetic animals with mild or high blood
glucose levels compared to control animals. (one-way ANOVA; n=11 for
control; n=6 for mild; n=5 for high)
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MiRNA

p-value

Fold Change

Angiogenic
Target

miR-330

0.004

27.21 increase

miR-139-5p

0.045

3.01 increase

SEMA 3A
NP-2
Rho-kinase 2

miR-497

0.013

4.70 decrease

Flk-1

let-7a

0.030

3.45 increase

TGF-β receptor

let-7c

0.023

3.43 increase

TGF-β receptor

miR-361

0.023

3.99 increase

VEGF-A

miR-127

0.031

5.93 decrease

VEGF-A
NP-1

Table 3.4. MicroRNAs involved in VEGF signaling.
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Figure 3.8. No change in p-Flk-1 (tyrosine 951) protein expression in
STZ-induced diabetic animals. Western analysis showed that
phosphorylation of Flk-1 at tyrosine 951 did not change in diabetic animals
compared to control. (one-way ANOVA; n=11 for control; n=6 for mild; n=5 for
high)
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Figure 3.9. No change in p-Flk-1 (tyrosine 1175) protein expression in STZinduced diabetic animals. Phosphorylation of Flk-1 at tyrosine 1175 did not
change in STZ animals compared to control. (one way ANOVA; n=10 for control;
n=5 for mild; n=5 for high)
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for p-Flk-1 (tyrosine 1214)/Flk-1
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Figure 3.10. No change in p-Flk-1 (tyrosine 1214) protein expression in STZinduced diabetic animals. Phosphorylation of Flk-1 at tyrosine 1214 did not
change in STZ animals compared to control. (one-way ANOVA; n=10 for control;
n=5 for mild; n=5 for high)
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Figure 3.11. No change in Src protein expresssion in STZ-induced diabetic
animals. Western analysis showed that global phosphorylation did not change in
Src, the downstream target of Flk-1 at tyrosine 951, in diabetic animals compared to
control. (n=8 for control; n=4 for mild; n=4 for high)
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Figure 3.12. No change in protein expression of PI3K in STZ-induced diabetic
animals. Phosphorylation of PI3K, the downstream target of Flk-1 at tyrosine 1175,
did not change in diabetic animals compared to control. (n=13 for control; n=7 for
mild; n=6 for high)
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Figure 3.13. No change in protein expression of Akt in STZ-induced diabetic
animals. Phosphorylation of Akt, the downstream target of Flk-1 at tyrosine 1175,
did not change in diabetic animals compared to control. (n=15 for control; n=9 for
mild; n=6 for high)
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Figure 3.14. Protein expression of PLCγ in STZ-induced diabetic animals.
Western analysis showed that there was a significantly greater phosphorylation of
PLCγ in diabetic animals with mild glucose levels compared to diabetic animals
high blood glucose levels. (n=12 for control; n=6 for mild; n= 6 for high)
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Figure 3.15. No change in protein expression of Erk 1/2 in STZ-induced
diabetic animals. Western analysis showed that there was no change in
phosphorylation of Erk 1/2 in diabetic animals compared to control. (n=14 for
control; n=9 for mild; n=5 for high)
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Figure 3.16. No change in protein expression of p38 in STZ-induced diabetic
animals. There was no change in phosphorylation of p38 in diabetic animals
compared to control. (n=10 for control; n=6 for mild; n=4 high)
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to decrease Flk-1 levels at the plasma membrane through modification and degradation
(Ewan et al., 2006).
Another explanation for the lack of effect of STZ treatment on Flk-1 expression is
that receptor levels are decreased in the post-natal brain (Kremer et al., 1997).
Therefore, it is possible that Flk-1 receptor expression is low in this diabetic model.
Maturation of Flk-1 involves glycosylation, resulting in 200 and 230 kDa forms of the
receptor. However, we were unable to detect Flk-1 at these molecular weights. A
fraction of the NP-1 receptor can be modified with either heparin or chondroitin sulfate,
and this modification is able to post-transcriptionally regulate Flk-1 expression (Shintani
et al., 2006). Although NP-1 protein levels did not change, it is possible that there is
enough modification of NP-1 receptors that could influence Flk-1 expression. VEGF
has been shown to mediate Flk-1/NP-1 complex (Soker et al., 2002). Since VEGF
protein levels did not change, then the Flk-1/NP-1 complex is less likely to form.
No change was observed in SEMA 3A protein levels in the diabetic animals.
Furthermore, the VEGF/SEMA 3A ratio was unchanged between control and diabetic
groups. An imbalance in this ratio in favor of VEGF would likely lead to activation of
several pathways involved in angiogenesis and permeability, such as migration and
proliferation. SEMA 3A is also a permeability factor acting through the neuropilin
receptor (Acevedo et al., 1998). Therefore, SEMA 3A competes with VEGF in binding
with the neuropilins. Additionally, VEGF has been shown to internalize the NP-1 in
endothelial cells when competing with SEMA 3A (Narazaki and Tosato, 2006).
Although the VEGF/SEMA 3A ratio did not change, this result could offer explanation for
no change in NP-1 protein levels.
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Although mRNA levels of VEGF, its receptors, and SEMA 3A increased in
diabetic animals compared to control, we did not see any changes at the protein level.
Recent studies have shown that circulating microRNA can play a significant role in
diabetes (Guay et al., 2011; Rottiers et al., 2012). MicroRNA are short, non-coding,
single-stranded RNAs, which regulate expression mRNA either by 1) complete
homology resulting in mRNA degradation or 2) imperfect homology leading to
translation repression. Circulating miRNAs that were significantly altered in STZinduced diabetic rats include miRNAs which regulate insulin receptors and insulin
binding proteins. In addition, there were miRNAs which could be involved in regulating
VEGF signaling. There was a significant up-regulation of miR-361 and a downregulation of miR-127, both of which target VEGF. Although there was no change in
VEGF protein levels, these miRNAs may be regulating VEGF expression. Additionally,
there was an up-regulation in miR-330, -26b, -let-7a/c, and -139-5p. SEMA 3A is a
potential target for miR-330, and up-regulation of miR-330 may contribute to the
mismatch between our SEMA 3A mRNA and protein measurements. There was also a
down-regulation in miR-497, which targets Flk-1. An increase in Flk-1 protein
expression would be expected. These discrepancies between mRNA and protein could
be due to miRNA interaction with AU-rich element binding proteins (ARE-BPs), which
together can regulate gene expression (Chang et al., 2011). Additionally, there could
be Dicer silencing, which would lead to total reduction of miRNAs and impairment of
VEGF-induced cellular processes (Suarez et al., 2008; Chang et al., 2011).
STZ treatment did not change Flk-1 phosphorylation at any of the tyrosine
residues. The neuropilins can regulate Flk-1, which could explain the lack of Flk-1
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phosphorylation and/or lack of VEGF-mediated formation of Flk-1/NP-1 complex.
Although Flk-1 phosphorylation did not change, we continued to look at downstream
targets of Flk-1. Phosphorylation of PI3K and Akt via activation of p-Flk-1 (tyrosine
1175) did not change in the diabetic groups compared to the control. Even though this
pathway has been shown to increase permeability in endothelial cells, it is not surprising
that phosphorylation of these downstream targets did not change since pFlk-1 levels did
not change. However, phosphorylation of PLCγ, also via activation of Flk-1 (tyrosine
1175) was significantly increased in diabetic animals with mild glucose levels compared
to animals with high glucose (P<0.012), but neither group showed significant difference
with the control animals. This pathway stimulates proliferation of endothelial cells,
which is important in angiogenesis, but it can also lead to eNOS activation and
subsequent permeability. Additionally, permeability can occur via PLCγ- dependent
influx of calcium (Holmes et al., 2007). However, Erk 1/2, the downstream target of
PLCγ, did not change in the diabetic group versus control. This is not surprising since
Erk 1/2 activity can be regulated by other proteins such as Ras (Hood et al., 2003) and
reactive oxygen species (Wang et al., 2004). Ras has also been shown to mediate
VEGF expression in Ras-induced Erk and HIF-1α activation (Wang et al., 2004). To
complicate matters, Ras activation is also dependent on integrins, and these integrins
can coordinate signaling pathways with VEGF (Hood et al., 2003). Activation of Flk-1
(tyrosine 951 and 1214) also did not yield changes in Src and p38 MAPK, respectively,
in the diabetic groups compared to control. A study by Kawamura et al. (2008) showed
that activation of p38 MAPK required both Flk-1 and NP-1 receptors. In our model,
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neither receptor showed any change in diabetic versus control groups. Therefore, it is
unlikely that p38 MAPK is involved in BBB permeability in diabetes.
Although there was an increase in gene expression of VEGF, its receptors, and
SEMA 3A, our study showed that protein levels did not change. Protein expression of
the components of the VEGF signaling system could be regulated by the abundance of
specific miRNAs. In addition, there was no change in the phosphorylation status of the
Flk-1 receptor. However, we were able to show a significant increase in PLCγ
phosphorylation between the two subgroups of the STZ-treated animals. Therefore, the
regulation of VEGF and its signaling pathways may, in part, be a mechanism for the
observed permeability increase in this diabetic animal model.
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Chapter 4: Discussion and Conclusions
Discussion
Diabetes is a significant problem in the United States, and complications include
retinopathy, cardiovascular disease, peripheral artery disease, nephropathy, and
neuropathy (Bonora et al., 2004; Pambianco et al., 2006). Many of these complications
are linked to microvascular pathologies. Diabetic patients are at risk for
cerebrovascular disease and neurodegeneration, and research has been aimed at the
role of the blood brain barrier (BBB) in this process. Several studies indicate that these
complications can arise from the loss of integrity of the BBB (Abbott, 2002; Zlokovic,
2008). Thus, the BBB is unable to effectively maintain its barrier characteristics and
becomes “leaky.” This leakiness is associated with decreased expression of tight
junction proteins, which serve to keep the endothelial cells of the BBB in close contact
and restrict paracellular transport (Hawkins et al., 2007). The first part of the study was
to determine if the molecular changes at the BBB could be attenuated by minocycline, a
tetracycline derivative. Furtherermore, I hypothesized that VEGF plays a role in
minocycline treatment. VEGF is a potent angiogenic and permeability factor that has
been implicated in vascular complications at the blood-retinal barrier in diabetes
(Antonetti et al., 1998). Minocycline has been shown to have an inhibitory effect on
VEGF. The aim of the second part of the study was to evaluate the potential role of
VEGF in diabetic BBB dysfunction.
Minocycline Studies
The STZ model of diabetes is a well-studied model, and we were able to show
that diabetic animals were hyperglycemic and exhibited increased ketone levels, which
are characteristics of TID. Additionally, BBB integrity is compromised in diabetes.
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Therefore, we hypothesized that minocycline would attenuate the observed BBB
changes in diabetes. We were able to show that minocycline does not affect blood
glucose levels or brain weights of these animals, suggesting that the drug does not
affect diabetes itself. Studies have shown that minocycline reduced infarct volumes in
MCAO models of ischemia (Yrjanheikki et al., 1999; Nagal et al., 2008; Matsukawa et
al., 2009). On the other hand, treatment with minocycline increased infarct volumes in
hypoxia-ischemia studies (Tsuji et al., 2004). These conflicting observations might be
due to start of treatment times, as the above studies reported treatment prior to
ischemic events, and duration of minocycline treatment. In our study, we treated the
animals with minocycline seven days after STZ injection in order to mimic a long term
treatment. Minocycline significantly decreased BBB permeability to sucrose in both
control and STZ-treated animals. Because previous studies in the laboratory have
reported a decrease in tight junction protein expression in this animal model in
conjunction with increased permeability (Hawkins et al., 2007), we predicted that
minocycline might exert its effects on these tight junction proteins. Treatment with
minocycline had no effect on occludin and ZO-1 protein expression; however,
minocycline significantly increased claudin-5 protein expression in both control and
STZ-treated animals. This observation was interesting because claudin-5 is considered
to be the primary seal for tight junctions (Hawkins and Davis, 2005). Minocycline may,
in part, function to improve claudin-5 expression. However, the mechanism of this
increase in expression is not known. Claudin-5 can be regulated by different
mechanisms, such as storage, recycling, post-translational modification, and inhibition
of specific signaling pathways such as the PKC pathway. Furthermore, MMP activity
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also affects claudin-5 expression. It would be interesting to investigate these various
avenues to determine how claudin-5 is regulated with minocycline treatment.
The next step was to determine if VEGF is involved in this minocycline-induced
increase in claudin-5. Previous studies have shown that VEGF regulates claudin-5
expression (Argaw et al., 2009). Furthermore, minocycline is able to promote VEGF
expression (Hollborn et al., 2010). We did not see any change in VEGF protein
expression in control and diabetic animals. However, we were able to show that VEGF
significantly increased in STZ-treated animals with minocycline, and a similar trend was
observed in control animals treated with minocycline. This increase in VEGF may be
due to a decrease in MMP expression and activity since minocycline has been shown to
decrease MMPs (Wasserman and Schlichter, 2007). MMPs degrade the extracellular
matrix, and previous work in the laboratory demonstrated an increase in MMP activity in
STZ-treated animals (Hawkins et al., 2007). The observed increase in VEGF levels with
minocycline treatment suggests that the extracellular matrix is relatively intact and the
majority of VEGF is bound to it. Future experiments could investigate whether
minocycline treatment decreases MMP activity in these animals.
We also found a significant increase in Flt-1 in control animals treated with
minocycline, and observed a similar trend in the minocycline-treated diabetic animals.
Interestingly, Flk-1 protein expression did not change with minocycline treatment, and
neither did the neuropilin receptors. Flt-1 is a decoy receptor, and may be scavenging
any VEGF that is secreted and thus inhibiting VEGF from binding the Flk-1 receptor.
Inhibiting VEGF binding would prevent the activation of downstream signaling pathways
that would lead to a permeability increase. It would be interesting to see if these
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signaling pathways affect claudin-5 expression in both control and minocycline-treated
diabetic animals.
STZ Studies
VEGF increased upon minocycline treatment in diabetic animals (Chapter 2).
Therefore, we studied the effects VEGF signaling might have on diabetes.
Furthermore, studies have demonstrated that VEGF can induce a permeability increase
and a decrease in tight junction expression in the blood vessels of the diabetic eye
(Antonetti et al., 1998). We were able to show that gene expression of VEGF, its
receptors, and its endogenous antagonist, SEMA 3A, increased in STZ-treated rats
compared to control in both cerebral microvessels and whole brain samples. VEGF and
VEGFR (Flt-1 and Flk-1) mRNA expression was higher in whole brain samples than in
cerebral microvessels. This result is expected since VEGF and its receptors are
present in other cell types in the brain (McCloskey et al., 2008). An increase in VEGF
and Flk-1 mRNA expression has been demonstrated in other studies (Hoehn et al.,
2002). However, we found that protein levels of VEGF did not change in the
microvessels or plasma of either group. This result was unexpected, as we would have
expected an increase in VEGF protein levels in the diabetic brain microvasculature.
Plate et al. (1992) demonstrated a low steady state level of expression of VEGF in
blood vessels in the normal brain. VEGF expression is up-regulated in various
pathological events. Since we observed an increase in mRNA expression of
components of the VEGF signaling system, but no change at the protein level, we
speculated that VEGF may undergo translational modification or that VEGF mRNA is
regulated. In collaboration with Dr. Santanam’s laboratory, we studied the potential
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regulation of VEGF via microRNAs. MicroRNAs are single stranded RNA that regulate
expression of mRNA. If the miRNA has 100% homology to the mRNA, then
degradation of the mRNA occurs. If there is partial homology, the mRNA undergoes
translation repression. Results indicate that up-regulation of miR-361 and downregulation of miR-127 in diabetic animals could offer an explanation as to why VEGF did
not change in this model of diabetes. miRNA-361 and -127 are known miRNAs that
target VEGF mRNA. Furthermore, VEGF may be bound to the extracellular matrix in
our model, which may also explain why we did not see any change in VEGF protein
expression in either the microvessels or plasma. Additionally, other cell types, such as
astrocytes, are able to secrete VEGF. Thus, additional experiments would be needed
to evaluate VEGF protein levels in the extracellular matrix and astrocytes.
Interestingly, we also did not see any change in protein expression of the VEGF
receptors, Flt-1, Flk-1 and NP-1. In the normal brain microvasculature, Flk-1 is downregulated due to a decrease in angiogenesis post-natally (Kremer et al., 1997). We
speculated that receptor expression would increase in the diabetic brain. An increase in
Flk-1 protein expression was observed in STZ-treated retinas (Hammes et al., 1998).
Additionally, it has been shown that VEGF is capable of up-regulating both mRNA and
protein expression of Flk-1 (Shen et al., 1998). However, our results are not fully
consistent in what has been reported in the literature.

Flk-1 undergoes glycosylation,

and we were able to show Flk-1 expression at 150 kDa, which is the immature receptor.
Intermediate glycosylated and mature Flk-1 receptor are present at 200 and 230 kDa,
respectively. As the receptor undergoes glycosylation, it will move to the plasma
membrane of the cell. We were not able to observe the fully mature and functional
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receptor, which may offer an explanation for the lack of change in receptor expression
at the two-week time point. We were, however, able to measure the activated receptor
via its phosphorylation. Therefore, it would be beneficial to extend the time point to see
if there are receptor changes. The Flt-1 receptor has higher affinity for VEGF than Flk1, and acts as adecoy receptor to sequester VEGF (Ferrara et al., 2003; Cebe-Suarez
et al., 2006).

Studies have shown that Flt-1 protein expression increased in intraretinal

vessels in proliferative diabetic retinopathy (Smith et al., 1999). Additionally, it has been
reported that VEGF is a major stimulus for Flt-1 up-regulation, especially in tumor
angiogenesis (Barleon et al., 1997). However, VEGF levels did not change in STZinduced diabetes, and may explain the lack of increase in Flt-1 expression.
The neuropilins function as co-receptors for VEGF signaling. We showed that
there was no change in NP-1 protein expression. We were unable to show NP-2
expression. NP-2 also functions to promote VEGF-stimulated pro-angiogenic activity.
Like NP-1, NP-2 can increase Flk-1 phosphorylation. It would be important to look at
NP-2 expression in this model. An important question to ask is if NP-1 and NP-2 levels
differ in this model, and if so, how does that affect VEGF signaling? NP-1 and NP-2 are
primarily expressed at the arterial and venous ends, respectively (Sulpice et al., 2008).
It is possible that the level of enhanced VEGF signaling is dependent on the location of
these co-receptors. Furthermore, it would be interesting to examine if there are different
affinities for Flk-1 binding between NP-1 and NP-2.
SEMA 3A is a ligand for the neuropilin receptors, and a competitive antagonist of
VEGF. When it binds to the neuropilin receptors, it inhibits VEGF-mediated
angiogenesis but can also induce permeability (Acevedo et al., 2008). We did not see
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any change in SEMA 3A expression in our diabetic animals. Furthermore, we did not
see changes in the VEGF:SEMA 3A ratio. If the ratio had changed in favor of VEGF, it
is possible that VEGF-induced signaling pathways might be more evident in this model.
It would be of interest to study SEMA 3A-induced permeability if the ratio had changed
in favor of SEMA 3A. Once SEMA 3A binds to the neuropilins, it must form a complex
with plexin A1, the signaling receptor for semaphorins. However, we were unable to
detect the plexin A1 protein expression in our model; however, it is not known if it is
absent altogether or if it was due to limitation of the antibody.
The lack of any observed changes in VEGF and its receptors prompted us to
look at how the VEGF signaling system is regulated. In collaboration with Dr.
Santanam, we investigated whether expression of VEGF is modulated by microRNAs.
Although not entirely complete, these results indicate that microRNAs might play an
important part in regulating the VEGF signaling system. In particular, the up-regulation
of miR-361 and the down-regulation of miR-124 are likely indicators of how VEGF
expression is modulated. One miRNA may be more effective in regulating VEGF
expression due to a closer match in homology. The studies of the miRNAs are
incomplete, and further investigation is needed to determine the role other miRNAs play
in VEGF signaling.
Finally, we looked at phosphorylation of Flk-1 and the downstream targets of its
signaling pathways. We looked at three phosphorylation sites (tyrosine 951, 1175, and
1214), but were unable to see any significant changes in the total phosphorylation.
However, it appears that there is a trend for an increase in phosphorylation for all sites
in diabetic animals with mild blood glucose, and a decrease in phosphorylation for all
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sites in diabetic animals with high blood glucose. This result could mean that in mildly
diabetic animals signaling pathways are activated, but by the time diabetes is at
uncontrolled and high glucose levels, the Flk-1signaling pathways are overwhelmed.
We looked at downstream targets of the Flk-1 phosphorylation sites. We did not see
any changes in PI3K and Akt, the downstream target of tyrosine 1175. This result was
somewhat unexpected because Akt will lead to the activation of eNOS to induce
vascular permeability. However, we did see a significant change in phosphorylation of
PLCγ, another downstream target of tyrosine 1175. To our knowledge, this result is a
novel finding. However, a downstream target of PLCγ, Erk 1/2, did not exhibit any
changes in phosphorylation. This observation is not discouraging since Erk 1/2
activation can be modulated by other signaling molecules, such as Ras. This change in
PLCγ is of particular interest because this is a known pathway of VEGF-induced tight
junction regulation. Inhibition of PLCγ activity leads to a hyperphosphorylation of tight
junction proteins (Ward et al., 2002). This hyperphosphorylation is believed to be due to
PKCα/β regulation of tight junction proteins. It would be beneficial to explore this
avenue as a permeability increase could be a multi-pathway event. Last, we did not see
any changes in Src and p38, the downstream targets of tyrosine 951 and 1214,
respectively.
It must also be remembered that we are looking at a single time point in a
dynamic process. Changes in the expression and activation levels of the VEGF system
are likely to be modulated throughout the time of the disease. Thus, future studies
would probably benefit from looking at multiple time points and perhaps concentrating
on either mild or high blood glucose levels.
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Conclusions
Vascular permeability and a decrease in tight junction protein expression are
evident in diabetes. My results show that the increased permeability can be attenuated
by the treatment of minocycline. The decreased permeability was in conjunction with an
increase in claudin-5 protein expression, known as the primary seal of the tight junction.
These results show promise for pharmacological treatment of cerebrovascular
complications of diabetes. It has been shown in these studies that VEGF protein
expression increased in diabetic animals upon minocycline treatment, perhaps making
VEGF more available. Thus, we wanted to further investigate VEGF in the observed
BBB changes in diabetes. The mechanism of increased permeability had not been
elucidated in the literature, but studies have been shown that VEGF is implicated in
vascular permeability in the diabetic eye. Therefore, we looked to see if VEGF is
involved in the vascular permeability. Although VEGF and its receptors did not exhibit
any changes at the protein level, we did observe a significant change in one of the
downstream targets, PLCγ, which is involved in gene expression and proliferation of
endothelial cells. Although the mechanism is not complete, this result is a starting point
to further investigate the role of the PLCγ signaling system in vascular permeability.
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